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10 Chapter 1
INTRODUCTION
In the early sixties of the last century, camptothecin (CPT) was isolated from the Chinese 
plant Camptotheca acuminata (Nyssaceae family),1 and was found to be a very potent 
antitumor agent in vitro.2 However, its clinical development was hindered by a relatively 
limited clinical activity and severe and unpredictable toxicities,3-6 most problematic be-
ing hemorrhagic cystitis and enteritis. These turned out to be partially related to the poor 
hydrophilicity of the drug and the initial administration of camptothecin in the inactive 
carboxylate form.7,8 Once the mechanism of action of camptothecin was discovered,9 
there was renewed interest in the drug. Eff orts were made to develop water-soluble 
camptothecin analogues with improved antitumor activity and decreased toxicity. Irino-
tecan, also known as CPT-11, was developed as a water-soluble prodrug of SN-38, a very 
potent camptothecin analogue,6,10 which has a 100-1000 fold higher cytotoxic activity 
in vitro than the parent compound.11,12 Camptothecins, including irinotecan and SN-38, 
inhibit the enzyme topoisomerase-I by binding to it and forming a stable complex 
between topoisomerase-I and DNA. This induces single-strand breaks in chromosomal 
DNA, ultimately leading to cytotoxicity and apoptosis.9,13
Irinotecan has a highly complex metabolism, involving multiple metabolizing phase 
I and phase II enzymes and several drug transporters (Figure 1). Irinotecan itself is not 
the active substance, but needs to be hydrolyzed by carboxylesterases into its active 
metabolite SN-38.14 These carboxylesterases are predominantly localized in the liver, but 
also in the lungs and in the mucosa of the gastrointestinal tract.15 However, only a small 
fraction of irinotecan is directly converted into SN-38. Competing with the formation 
of SN-38 is the CYP3A-mediated oxidation of irinotecan into the inactive metabolites 
NPC and APC, and the structurally unresolved metabolite M4. NPC and APC both also 
can be converted into SN-38 by carboxylesterases; NPC has the same affi  nity as irino-
tecan, but APC is a very poor carboxylesterase-substrate.16 SN-38 is mainly eliminated 
via glucuronidation into SN-38 glucuronide (SN-38G), which involves several UGT1A 
enzymes;17 UGT1A1 being the most important.18 After biliary excretion, SN-38G can be 
re-activated into SN-38 by β-glucuronidase-producing bacteria in the intestines. This 
reactivation is thought to have a causative role in irinotecan’s intestinal toxicity.19 In 
addition, several drug-transporting proteins are involved in the cellular uptake (Organic 
Anion Transporting Polypeptides; OATP1B1 and OATP1B3)20,21 and the hepatobiliary and 
renal elimination of irinotecan and its metabolites (ATP Binding Cassette transporters; 
ABCB1 (P-glycoprotein), ABCC1 (MRP), ABCC2 (cMOAT), and ABCG2 (BCRP)).22-27 To make 
it even more complex, both irinotecan and SN-38 exist in an active lactone form and an 
inactive carboxylate form. There is a pH-dependent equilibrium between the two; an 
acidic pH promotes the formation of the lactone form, while a physiological pH favors 
the carboxylate form.28,29
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Figure 1. Metabolism of irinotecan
After intravenous infusion, irinotecan is distributed throughout the body. It is metabolized into the 
active metabolite SN-38 by carboxylesterases (CES), which are predominantly localized in the liver, but 
also in the lungs and the mucosa of the gastrointestinal tract. In addition, irinotecan is being oxidized 
by CYP3A enzymes into the inactive metabolites APC, M4, and NPC; the latter also being a substrate 
for CES-mediated conversion into SN-38. SN-38 is inactivated by UGT1A enzymes, UGT1A1 being the 
most important, into its glucuronide-conjugate SN-38G. After hepatobiliary excretion, SN-38G can be 
reactivated into SN-38 by β-glucuronidase (β-GLUC) producing bacteria. Several uptake (Solute Carrier 
Organic Anion (SLCO) transporter family) and effl  ux transporters (ATP-binding cassette (ABC) transporter 
family) are involved in the elimination of irinotecan.
Copyright PharmGKB. Re-published with permission from PharmGKB and Stanford University.
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Early clinical studies with irinotecan were performed in the nineties and showed 
responses in patients with colorectal cancer, and several other solid and hematological 
malignancies, such as lung, breast, esophageal, head and neck, pancreatic, renal cell, 
cervical, and ovarian cancer, leukemia and lymphoma.6,30 In 1996, irinotecan received 
accelerated approval in the USA for the treatment of metastatic colorectal cancer after 
failure of fl uorouracil (5-FU)-based therapy. Two years later it was approved in the Neth-
erlands. Currently, irinotecan is used in combination therapy and as single agent in the 
fi rst-line and second-line treatment of colorectal cancer, as it prolongs life and improves 
the quality of life.31-33
Although irinotecan is an active drug, it is notorious in clinical practice because of 
its unpredictable and severe toxicities, mainly diarrhea and neutropenia. Many years 
of research have given some more insight in the pathophysiology and predictors of 
these toxicities.34 However, until now there is no clear explanation for the interpatient 
variability in exposure and effi  cacy of irinotecan. Body surface area (BSA)-based dosing 
of irinotecan does not reduce this variability,35 which makes BSA-based dosing useless 
in the case of irinotecan, as it is for many other anticancer drugs.36 Although fl at-fi xed 
dosing seems a good alternative because it is simpler and safer (as no calculation errors 
can be made),37 the interpatient variability in pharmacokinetics and toxicities remains 
the same. Therefore, a new dosing algorithm on the basis of patient characteristics that 
are known to infl uence the pharmacokinetics, toxicities and effi  cacy of irinotecan, is 
necessary to truly personalize irinotecan therapy. 
In general, interpatient variability in drug exposure and effi  cacy can be explained by 
several factors, both inherited (genetic) and environmental (Figure 2). Since the start of 
the Human Genome Project in which all human genes and base pairs were analyzed,38 
much focus has been put on polymorphisms in metabolizing enzymes and drug trans-
porters to explain the large interpatient variability that is seen with many anticancer 
drugs. In the case of irinotecan, much focus was put on the UGT1A1*28 polymorphism, a 
promoter repeat in the TATA-box of the UGT1A1 gene, that results in a reduced formation 
of the enzyme UGT1A1.39,40 In addition, several other polymorphisms in the metabolic 
pathway of irinotecan and their role in the variability of pharmacokinetics and toxici-
ties were investigated.41-46 However, although UGT1A1*28 and other polymorphisms do 
explain a part of the interpatient variability of the pharmacokinetics and toxicities of 
irinotecan, it is not the holy grail.47,48
As already mentioned, not only genetic but also environmental factors play a role in 
pharmacokinetic variability. In the case of irinotecan, the eff ect of several concomitant 
drugs and herbal products has already been investigated, such as combinations of 
irinotecan with ketoconazole, valproic acid, St John’s wort, medical cannabis, and milk 
thistle.49-53 However, the eff ect of other environmental factors, such as comorbidity and 
lifestyle is scarcely investigated and other drug-drug interactions could also play a role.
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In addition to indirect ways of reducing toxicities by reducing the variability in phar-
macokinetics, direct ways to decrease irinotecan’s toxicities also have been explored, 
especially for diarrhea. Although nowadays diarrhea is manageable by using high-dose 
loperamide and antibiotics, prediction and more importantly prevention of the occur-
rence of diarrhea remains diffi  cult. Strategies for reducing intestinal toxicity have mainly 
been aimed on preventing the reactivation of SN-38 by β-glucuronidase producing 
bacteria and the absorption of unbound intestinal SN-38. These include the adminis-
tration of neomycin, cholestyramine/levofl oxacin, activated charcoal, budesonide and 
compounds that promote intestinal alkalization.54-60
Disease Treatment Patient
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•Clinical Performance
•Route of Administration
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•Gender
•Age
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Figure 2. Factors aff ecting the interpatient variability of drug therapy
Abbreviations: OTC, over the counter; PK, pharmacokinetics; PD, pharmacodynamics.
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AIMS OF THE THESIS
This thesis describes research that was performed in order to add new tools into the 
toolbox of personalized irinotecan treatment. We set out to fi nd new factors that explain 
the relatively large interpatient variability in pharmacokinetics and toxicity of irinote-
can. Several factors were taken into consideration, such as life style factors (smoking) 
in Chapter 2, genetic factors (mannose-binding lectin polymorphisms) in Chapter 3; 
comorbidity (renal failure) in Chapter 4 and co-medication in Chapter 5 (omeprazole) 
and Chapter 6 (strumazole). Finally, Chapter 7 describes a new individualized dosing 
model for irinotecan based on the most predictive patient characteristics. The aim of 
this research was to gain knowledge with respect to interpatient variability in pharma-
cokinetics and toxicities of irinotecan, with the ultimate aim to personalize treatment for 
each single patient on the basis of his/her characteristics. 
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Cigarette smoking and 
irinotecan treatment: 
pharmacokinetic interaction 
and eff ects on neutropenia
JM van der Bol, RH Mathijssen, WJ Loos, LE Friberg, RH van Schaik, 
MJ de Jonge, AS Planting, J Verweij, A Sparreboom, FA de Jong
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ABSTRACT 
Purpose 
Several constituents of cigarette smoke are known to interact with drug-metabolizing 
enzymes and potentially aff ect treatment outcome with substrate drugs. The purpose of 
this study was to determine the eff ects of cigarette smoking on the pharmacokinetics 
and adverse eff ects of irinotecan.
Patients and methods 
A total of 190 patients (49 smokers, 141 non-smokers) treated with irinotecan (90-minute 
intravenous administration on a three-weekly schedule) were evaluated for pharmaco-
kinetics. Complete toxicity data were available in a subset of 134 patients receiving 350 
mg/m2 or 600 mg fl at-fi xed dose irinotecan.
Results 
In smokers, the dose-normalized area under the plasma concentration-time curve of 
irinotecan was signifi cantly lower (median, 28.7 versus 33.9 ng×h/mL/mg; P = .001) com-
pared with non-smokers. In addition, smokers showed an almost 40% lower exposure to 
SN-38 (median, 0.54 versus 0.87 ng×h/mL/mg; P = .001) and a higher relative extent of 
glucuronidation of SN-38 into SN-38G (median, 6.6 versus 4.5; P = .006). Smokers experi-
enced considerably less hematologic toxicity. In particular, the incidence of grade 3 to 4 
neutropenia was 6% in smokers versus 38% in non-smokers (odds ratio [OR], 0.10; 95% 
CI, 0.02 to 0.43; P = .001). There was no signifi cant diff erence in incidence of delayed-
onset diarrhea (6% versus 15%; OR, 0.34; 95% CI, 0.07 to 1.57; P = .149).
Conclusion 
This study indicates that smoking signifi cantly lowers both the exposure to irinotecan 
and treatment-induced neutropenia, indicating a potential risk of treatment failure. 
Although the underlying mechanism is not entirely clear, modulation of CYP3A and 
uridine diphosphate glucuronosyltransferase isoform 1A1 may be part of the explana-
tion. The data suggest that additional investigation is warranted to determine whether 
smokers are at increased risk for treatment failure.
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INTRODUCTION
Tobacco is the single largest preventable cause of cancer in the modern world.1 It ac-
counts for approximately 30% of all cancer deaths. In addition to the fact that it explains 
almost 90% of lung cancer deaths, it is linked to more than ten diff erent cancer types, 
including cancer of the head and neck, esophagus, bladder, pancreas, cervix, kidney, 
stomach, colon, and rectum, and some leukemias, as well as to an earlier onset of cancer 
and to a worse prognosis.2-4 Despite all antismoking campaigns, there are currently 
about 1.3 billion smokers worldwide and this number is still increasing.5 Interestingly, 
little data are available on the prevalence of smoking in cancer patients. At the M.D. An-
derson Cancer Center (Houston, TX), smoking rates of 30% among both male and female 
cancer patients were reported.6 In addition, 25% of patients referred to the Canadian 
Ottawa Regional Cancer Center were smoking.7 These numbers are in concordance with 
smoking prevalence in the general population in the Americas, with estimates of 24% to 
32% among men and 18% to 21% among women, respectively.5,8
Cigarette smoke contains several constituents known to interact with drug-metabo-
lizing enzymes. For example, polycyclic aromatic hydrocarbons (PAHs) induce CYP1A1 
and CYP1A2,9 both of which are isoforms of the cytochrome P-450 family (CYP) that is 
involved in the metabolism of almost all anticancer drugs,10 thereby interfering with 
the pharmacokinetic profi le of drugs metabolized by these CYPs. For instance, the oral 
clearance of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, was 
shown to be 24% faster in smokers compared with non-smokers,11 and this may aff ect 
overall survival in non-small cell lung cancer.12
PAHs are also known to induce some isoforms of the uridine diphosphate glucurono-
syltransferase (UGT) family,9 which includes important enzymes involved in glucuronic 
acid conjugation. For example, increased rates of glucuronidation of propranolol and 
codeine have been reported in smokers.13,14 In addition to PAHs, other cigarette con-
stituents such as nicotine, carbon monoxide, and cadmium may also be involved in 
modulation of the expression and function of enzymes and drug transporters involved 
in drug elimination.15,16
Against this background, the purpose of this study was to explore the eff ect of smok-
ing behavior on the pharmacokinetics and adverse eff ects of irinotecan (Campto; Pfi zer, 
Capelle aan den IJssel, the Netherlands), a topoisomerase-I inhibitor registered for the 
fi rst-line and second-line treatment of metastasized and/or inoperable colorectal can-
cer, which is known to be a substrate for several cytochrome P-450 and UGT1A isozymes 
(Figure 1) and drug transporters, in a large cohort of cancer patients.
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PATIENTS AND METHODS
Patients
A total of 202 patients, previously enrolled in nine diff erent prospective clinical trials 
with irinotecan between 1996 and 2005 that involved pharmacokinetic analyses,17-25 
were included in this study. The common inclusion criteria were a histologically or cy-
tologically confi rmed diagnosis of any form of cancer that was believed to be sensitive 
to irinotecan or for which no other treatment options were available; age older than 18 
years; Eastern Cooperative Oncology Group/WHO performance score less than 2; and 
adequate hematopoietic, hepatic, and renal functions. A specifi c exclusion criterion for 
the current analysis was the use of known CYP3A or UGT1A inducers or inhibitors. All tri-
als were conducted according to the revised Declaration of Helsinki and were approved 
by the local medical ethical committee. Written informed consent was obtained from all 
patients. 
Treatment
Patients received irinotecan once every three weeks as a 90-minute intravenous infusion 
at doses ranging from 175 to 350 mg/m2 or a 600 mg fl at-fi xed dose. Patients received 
prophylactic antiemetics and atropine was administered if acute cholinergic syndrome 
occurred. For the treatment of irinotecan-induced delayed-onset diarrhea, patients 
received a treatment scheme with loperamide and, if necessary, antibiotics.
Figure 1. Metabolism of irinotecan 
Irinotecan is mainly metabolized by carboxylesterases (CES) forming active SN-38 that is subsequently 
glucuronidized into SN-38G by uridine diphosphate glucuronosyltransferase (UGT1A). After hepatobiliary 
excretion, SN-38 is the subject of bacterial β-glucuronidase-mediated reactivation. Alternatively, 
irinotecan is inactivated by cytochrome P-450 3A (CYP3A) mediated oxidation into APC and NPC, which 
can be activated by carboxylesterases.
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Smoking status
Patients were categorized as smokers or non-smokers based on information retrieved 
from medical fi les from patient interviews performed on the day before commencing 
treatment. Former smokers were classifi ed as non-smokers. To use a safe washout period 
for possible enzyme induction, patients who reported they had stopped smoking within 
4 weeks before treatment were excluded from analysis.
Pharmacokinetic analysis
Blood samples of 5 to 7 mL were collected for measurements of irinotecan, SN-38, and 
SN-38G at serial time points up to 500 hours after infusion. Samples were handled and 
analyzed by high-performance liquid chromatography as described elsewhere.26-29 Indi-
vidual pharmacokinetic parameters were derived as empirical Bayes estimates and were 
predicted using a previously developed population model,30 and the POSTHOC option 
in the software package NONMEM version V (Globomax, Hanover, MD). Clearances were 
calculated as the dose divided by the area under the plasma concentration-time curve 
(AUC). Clearances of SN-38 and SN-38G are actually metabolic clearances (i.e., clearance 
divided by metabolic fraction, for which no assumption in each individual patient was 
made). Dose-normalized AUCs were calculated as AUC divided by dose. 
Relative extent of conversion of irinotecan into SN-38 (percentage), calculated as 
the molar AUC0 to 100 hours ratio of SN-38 to irinotecan ×100%, and the relative extent of 
glucuronidation of SN-38 into SN-38G, defi ned as the molar AUC0 to 100 hours ratio of SN-38G 
to SN-38, were considered as well. Although these measures refl ect carboxylesterase 
capacity and UGT1A capacity, respectively, both measures are actually surrogate mea-
sures.31 Other factors, although less pronounced, may aff ect the measures as well, such 
as CYP3A-mediated inactivation and adenosine triphosphate binding cassette (ABC) 
drug transporter-mediated excretion.
UGT1A1*28 genotyping
UGT1A1 genotype analysis was performed for the presence of an additional (seventh) 
repeat in the promoter region of UGT1A1 (i.e., UGT1A1*28) in whole blood, as described 
elsewhere.23 Patients homozygous for six repeats (wild type) were assigned as TA6/TA6, 
patients homozygous for seven repeats were assigned as TA7/TA7, and heterozygous 
patients were assigned as TA6/TA7.
CYP3A phenotyping
In a subset of 30 patients, midazolam and erythromycin were administered as phenotyp-
ing probes for CYP3A. Both tests (i.e., the midazolam clearance test and the erythromycin 
breath test) have been described in detail elsewhere.23
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Pharmacodynamic analysis
Complete blood counts with diff erential, including white blood cell (WBC) count and ab-
solute neutrophil count (ANC), and clinical chemistry data were determined at baseline 
and weekly during the three-week follow-up period. Pharmacodynamic relationships 
were investigated in the subgroup of patients who had received single agent irinotecan 
at the registered dose of 350 mg/m2 or the 600 mg dose equivalent.32 Leukopenia, neu-
tropenia, and diarrhea were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 3.0, and were dichotomized further in 
no/mild (grade 0 to 2) and severe (grade 3 to 4) toxicity.33 In addition, hematologic toxic-
ity was evaluated using absolute nadir and percentage decrease at nadir from baseline, 
defi ned as: percentage decrease = (baseline value  nadir value)/baseline value x 100%.
Statistical analysis
Data are presented as median and range, unless stated otherwise. To compare continu-
ous variables between smokers and non-smokers, the Mann-Whitney U test was used. 
Spearman’s ρ correlation coeffi  cient was used for relating two continuous variables. If 
two dichotomous variables were obtained, odds ratios were calculated and a χ2-test 
was used to calculate a corresponding P-value. Based on a Bonferroni correction for 
fi ve variables,34 two-sided P < .01 were considered signifi cant. All statistical tests were 
performed with SPSS version 14.0.0 (SPSS Inc, Chicago, IL).
RESULTS
Patients
A total of 190 patients (49 smokers and 141 non-smokers; Table 1) were assessable for 
analysis of the infl uence of smoking on the pharmacokinetic parameters of irinotecan. 
For 10 patients, smoking status could not be obtained with certainty. Two patients 
reported having quit smoking within 4 weeks before treatment and therefore were 
considered not eligible. Other former smokers quit smoking at least 2 months before 
their fi rst irinotecan treatment and were thus considered as non-smokers. Except for age 
and bilirubin, none of the baseline demographic data, including UGT1A1*28 genotype 
status, were signifi cantly diff erent between smokers and non-smokers (Table 1).
Smoking and irinotecan pharmacokinetics
Smokers showed about an 18% faster clearance of irinotecan than non-smokers (median, 
34.8 versus 29.5 L/h; P = .001; Table 2). The systemic exposure to the active metabolite 
SN-38 was almost 40% lower in smokers (median dose-normalized AUC0 to 100 hours, 0.54 
versus 0.87 ng×h/mL/mg; P < .001), whereas no signifi cant eff ect on the glucuronide 
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Table 1. Patient characteristics 
Parameter
All patients Non-smokers Smokers
PaN % N % N %
Total number of patients 190 100 141 74 49 26
Sex .584b
Male 110 58 80 57 30 61
Female 80 42 61 43 19 39
Age, years .001
Median 54 56 49
Range 24-75 24-75 27-70
BSA (m2) .594
Median 1.88 1.88 1.89
Range 1.29-2.40 1.29-2.40 1.46-2.36
Tumor type .123b
Colorectal 78 41 66 47 12 24
Lung 25 13 16 11 9 18
(A)CUP 28 15 19 13 9 18
Pancreas/biliary tract 18 9 12 9 6 12
Esophageal/gastric 17 9 13 9 4 8
Miscellaneous 24 13 15 11 9 18
UGT1A1 genotype 128 93 35 .312b
TA6/TA6 64 50 43 46 21 60
TA6/TA7 56 44 43 46 13 37
TA7/TA7 8 6 7 7 1 3
Baseline hematology
Platelets (×109/L) .917
Median 296 296 297
Range 99-966 117-966 99-586
WBC (×109/L) .077
Median 7.9 7.8 8.4
Range 2.8-27.0 2.8-27.0 4.4-15.7
ANC (×109/L) .176
Median 5.5 5.4 6.1
Range 1.5-24.0 1.5-24.0 3.0-12.1
Hemoglobin (g/dL) .412
Median 12.7 12.6 12.7
Range 8.4-16.7 8.5-16.7 8.4-15.1
Hematocrit (L/L) .314
Median 0.38 0.38 0.38
Range 0.27-0.50 0.27-0.50 0.27-0.46
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conjugate of SN-38 (i.e., SN-38G) was observed (Table 2). Mean dose-normalized plasma 
concentration-time profi les of both irinotecan and SN-38 for smokers and non-smokers 
are shown in Figure 2. In addition, the relative extent of conversion of irinotecan into 
SN-38, and in particular, the relative extent of glucuronidation of SN-38 into SN-38G, 
were signifi cantly diff erent between both groups; the relative extent of conversion was 
lower (median, 2.9% versus 3.8%; P < .001) and the relative extent of glucuronidation 
was higher in smokers (median, 6.6 versus 4.5; P = .006; Table 2). No dose-eff ect relation-
ship could be established between the pharmacokinetic parameters and the amount of 
smoked cigarettes (data not shown). 
Parameter
All patients Non-smokers Smokers
PaN % N % N %
Baseline chemistry
Albumin (g/L) .754
Median 41 41 41
Range 20-53 20-53 31-53
Total bilirubin (μmol/L) < .001
Median 8 9 7
Range 1-26 3-26 1-18
Alk phos (U/L) .552
Median 108 109 106
Range 26-925 26-925 29-722
GGT (U/L) .042
Median 57 61 44
Range 7-1,437 7-1,437 10-1,364
AST (U/L) .049
Median 26 29 24
Range 6-185 6-185 7-106
ALT (U/L) .109
Median 19 20 16
Range 3-225 5-225 3-87
Creatinine (μmol/L) .477
Median 77 76 78
Range 44-151 44-151 45-134
Abbreviations: BSA, body surface area; (A)CUP, (adeno) carcinoma of unknown primary; UGT1A1, uridine 
diphosphate glucuronosyltransferase isoform 1A1; ANC, absolute neutrophil count; Alk phos, alkaline 
phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl 
transpeptidase; WBC, white blood cell count. 
a Two-sided Mann-Whitney U test, unless stated otherwise. 
b χ2-test (variable categories versus smoking status).
Table 1. continued
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In the subgroup of patients not carrying a single UGT1A1*28 allele (i.e., TA6/TA6 
patients), results were comparable. In particular, systemic exposure to SN-38 was sig-
nifi cantly lower in smokers (N = 21) compared with non-smokers (N = 43; median dose-
normalized AUC0 to 100 hours, 0.54 versus 0.82 ng×h/mL/mg; P < .001). Likewise, the relative 
extent of glucuronidation was higher in smokers (median, 6.75 versus 4.41; P = .006).
Smoking and CYP3A phenotype
Thirty patients (10 smokers and 20 non-smokers) were tested for CYP3A phenotype 
using the midazolam clearance test and the erythromycin breath test. Pharmacokinetic 
parameters in this group were representative of the entire population. Although smok-
ers showed a somewhat lower exposure to both midazolam (t4 hours) and erythromycin, 
indicating higher CYP3A activity, no signifi cant diff erences were found between both 
groups (Table 3).
Smoking and irinotecan-related toxicity
In the subgroup of patients treated with the registered dose of irinotecan (350 mg/m2 
or a 600 mg fl at-fi xed dose), smokers (N = 35) experienced signifi cantly less hematologic 
toxicity than non-smokers (N = 99). Specifi cally, the median WBC values decreased to 
5.3 ×109/L in smokers and 3.0 ×109/L in non-smokers (P < .001), whereas the respective 
ANC nadir values were 3.3 ×109/L versus 1.6 ×109/L (P < .001). Incidences of grade 3 to 4 
leukopenia (9% versus 32%; OR, 0.20; 95%CI, 0.06 to 0.69; P = .006) and neutropenia (6% 
versus 38%; OR, 0.10; 95% CI, 0.02 to 0.43; P < .001) were signifi cantly lower in smokers 
Figure 2. Mean dose-normalized plasma concentration-time curves (± 95% CI) of irinotecan and SN-38 in 
smokers and non-smokers (N = 190). 
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compared with non-smokers (Table 4). The AUC0 to 100 hours of both irinotecan and SN-38 
were correlated with both the nadir of WBC (ρ = –.434 and ρ = –.582, respectively; P < 
.001) and the nadir of ANC (ρ = –.394 and ρ = –.593, respectively; P < .001). Although the 
incidence of grade 3 to 4 diarrhea was 60% lower in smokers, no signifi cant diff erence 
between smokers and non-smokers was found (6% versus 15%; OR, 0.34; 95% CI, 0.07 to 
1.57; P < .149).
DISCUSSION
This study suggests that smoking signifi cantly aff ects the pharmacokinetics and toxic-
ity profi le of irinotecan. The clearance of irinotecan was signifi cantly faster in smokers. 
In addition, smokers showed a more extensive glucuronidation of SN-38, resulting in 
reduced systemic exposure to the active metabolite SN-38, which likely contributed 
to less severe hematologic toxicity. The data complement previous knowledge on the 
clinical pharmacology of irinotecan, and may have important practical implications for 
its optimal use. The incentive for this study was the recent fi nding that smoking might 
aff ect the partitioning of irinotecan in red blood cells in vitro.35 In addition, because 
irinotecan is subject to a highly complex metabolic pathway, involving several phase I 
and II enzymes and drug transporters (Figure 1), an eff ect of individual constituents of 
cigarette smoke on these metabolic pathways was hypothesized. 
The decreased exposure to irinotecan in smokers observed in this study may be ex-
plained by induction of CYPs. Although irinotecan is not metabolized by CYPs typically 
associated with drug interactions caused by smoking, such as CYP1A1 and CYP1A2,36,37 
it is known to be highly sensitive to CYP3A induction.24 Previous studies have suggested 
that smoking may induce CYP3A. For example, the systemic exposure to quinine, a 
Table 3. Eff ect of smoking behavior on CYP3A phenotype 
Parameter
Non-smokers (N = 20) Smokers (N = 10)
PaMedian Range Median Range
Erythromycin breath test
CER20 (% dose/min) 0.018 0.006-0.045 0.016 0.008-0.032 .746
AUCCER 0-40 (% dose) 0.63 0.22-1.53 0.57 0.26-1.11 .779
1/tmax (1/min) 0.064 0.041-0.097 0.066 0.045-0.111 .559
Midazolam clearance test
t4 hours (ng/ml) 4.05 1.19-12.71 3.51 1.81-9.54 .373
CL (mL/min) 650 261-877 556 332-1,012 .999
Abbreviations: CER20, fl ux of exhaled radiolabeled CO2 at time 20 minutes; AUCCER 0-40, area under the 
fl ux of exhaled radiolabeled CO2-time curve from 0 to 40 minutes; 1/tmax, reciprocal of time to peak 
concentration; t4 hours, midazolam concentration in the 4-hour sample; CL, clearance. 
a Two-sided Mann Whitney U test. 
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known CYP3A substrate, was found to be 44% lower in smokers compared with non-
smokers.38,39 In addition, in two in vitro studies, nicotine, the addictive constituent of 
cigarettes, caused induction of CYP3A transcription by activating the nuclear receptor 
NR1I2 (pregnane X receptor).40,41 The possibility of CYP3A modulation by cigarette smok-
ing is supported by the current fi nding that measures of exposure to the CYP3A probe 
drugs midazolam and erythromycin were lower in smokers, although this did not reach 
statistical signifi cance, presumably due to the small sample size studied. It is notable 
that reduced systemic exposure in smokers has also been reported for the CYP3A4 phe-
notyping probe alprazolam.42 However, other studies involving CYP3A substrates have 
not confi rmed this infl uence of smoking,43-46 suggesting that, if CYP3A is the causative 
regulator, this eff ect might be dependent on the substrate drug. 
Alternatively, modulation of carboxylesterases could explain the eff ects on irinotecan 
clearance and the relative extent of conversion of irinotecan into SN-38. Indeed, the rela-
tive extent of conversion is lower in smokers, at fi rst suggesting inhibition of carboxyles-
terases and less eff ective conversion of irinotecan into SN-38. However, confl icting with 
this hypothesis, smokers were found to have lower systemic concentrations of irinote-
can. Apart from CYP3A modulation, this latter fi nding might be explained by induction 
of functional expression of carboxylesterases. In this case, the apparent lower extent of 
conversion of irinotecan into SN-38 should be attributed to a higher glucuronidation 
of SN-38 into SN-38G, compensating for the metabolism of additionally formed SN-38. 
Indeed, there is some in vitro research supporting the hypothesis that carboxylesterases 
might be modulated by certain PAHs found in cigarette smoke.47 However, to date, there 
are insuffi  cient data to draw any conclusions regarding the infl uence of smoking on 
carboxylesterase activity in relation to irinotecan therapy. 
In addition to CYPs and carboxylesterases, cigarette smoke is also known to induce 
glucuronidation of certain drugs.48,49 Furthermore, there is evidence that cigarette con-
stituents can specifi cally induce UGT1A.50,51 The higher relative extent of glucuronidation 
of SN-38 into SN-38G observed in smokers can be explained by induction of UGT1A1. To 
excrete the breakdown products of hemoglobin, bilirubin is glucuronidized by UGT1A1. 
In line with earlier published data,52-63 somewhat lower baseline bilirubin concentra-
tions in smokers were found in the current study (median, 7.0 versus 9.0 μmol/L; P < 
.001), indicating that smoking cigarettes may induce UGT1A1. This theory has also been 
proposed by others,64 although the lower bilirubin concentration in smokers might also 
be explained by an eff ect on specifi c drug transporters, such as ABCC2 (canalicular mul-
tispecifi c organic anion transporter) and the organic anion transporting polypeptide 8. 
Given that the distribution of UGT1A1*28, which is known to be related to both bilirubin 
levels and clearance of SN-38, did not diff er between smokers and non-smokers, it is 
unlikely that the diff erent bilirubin levels can be attributed to diff erences in UGT1A1*28 
status. The lower exposure to SN-38 in smokers is in line with the lower bilirubin level in 
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this group of patients and strongly suggests that cigarette smoke induces UGT1A1, indi-
rectly lowering the risk of severe adverse eff ects and the chance of therapeutic benefi t 
as a consequence of the lower SN-38 exposure. 
Indeed, in this study, smokers had remarkably less hematologic toxicity. Although 
smokers are known to have higher WBC counts,65-67 in this particular population the 
baseline WBC counts in smokers were only marginally higher (P = .077 and P = .176 for 
WBC and ANC, respectively; Table 1), suggesting that the higher nadirs and the smaller 
percentage decrease at nadir seen in smokers during irinotecan therapy cannot be at-
tributed solely to the direct eff ects of their smoking habit on bone marrow function. 
Whether the therapeutic outcome was aff ected could not be investigated reliably in 
the present study because of the design of the conducted trials and the heterogeneity 
of the included patients. Induction of other UGT1A enzymes known to be capable of 
SN-38 glucuronidation, such as UGT1A7 and UGT1A9,68,69 should not be disregarded. 
Whether the higher glucuronidation capacity in smokers is to be attributed to induction 
of UGT1A isoforms expressed in the liver or extrahepatically remains to be investigated. 
For example, Villard et al,49 found that mice exposed to cigarette smoke had enhanced 
glucuronidation capacity in the liver and particularly in the lung. 
In addition to these eff ects on phase I and II enzymes, induction of ABC transporters 
by smoking can result in faster elimination of irinotecan and its metabolites, and hence in 
decreased exposure.68 In rats, increased expression of placental ABCB1 (P-glycoprotein) 
was observed after tobacco exposure,70 indicating that cigarette smoke may infl uence 
irinotecan pharmacokinetics via modulation of ABC transporters. Furthermore, im-
munohistochemical analysis of non-small cell lung carcinomas in 94 patients revealed 
higher ABCB1 expression in smokers (58% versus 9%; P < .001).71 However, no diff erence 
in placental expression of ABCB1 and ABCG2 (breast cancer resistance protein) was seen 
between smoking and non-smoking mothers.72 In addition, no eff ect of nicotine me-
tabolites on organic anion transport by ABCC2 (canalicular multispecifi c organic anion 
transporter) was found in vitro.73 In summary, at present, there are insuffi  cient data to 
make conclusions regarding the infl uence of smoking on ABC transporters.
Although additional investigation is required to determine the underlying mecha-
nism of the current observations, they may have important clinical implications. Smok-
ing before and during irinotecan treatment seems to have unfavorable eff ects. The data 
presented suggest that knowledge of smoking behavior before irinotecan treatment 
needs to be taken into consideration. Given that our analysis was conducted retrospec-
tively in a heterogeneous patient population, recommendations regarding dose adjust-
ments for smokers or smoking cessation during irinotecan treatment cannot be made 
at present. In addition, no data are available about the eff ect of smoking on outcome of 
irinotecan treatment. Furthermore, infl uence of smoking also should be investigated in 
the frequently used combination schemes with irinotecan. 
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In conclusion, this study suggests that smoking is associated with reduced systemic 
exposure to irinotecan and its active metabolite SN-38, and subsequently, less severe 
hematologic toxicity. Given that they both more or less depend on systemic irinotecan 
and SN-38 exposure, less hematologic toxicity indirectly may refl ect a less favorable 
therapeutic outcome. Therefore, it should be stressed that the lower incidence and less 
severity of hematologic toxicity of irinotecan therapy in smoking patients is likely an 
unbalanced and unwanted adverse eff ect. Although the underlying actual mechanism 
is not completely clear, the eff ects on irinotecan pharmacokinetics probably can be as-
cribed to modulation of enzymes involved in the metabolism of irinotecan, in particular 
CYP3A and UGT1A1. Although results presented in this article indicate that therapeutic 
outcome of irinotecan might be aff ected negatively by smoking, whether smokers 
should quit smoking or should receive a higher dose (if smoking cessation is not an 
option) to achieve equal outcome to irinotecan treatment as non-smokers remains to 
be investigated.
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ABSTRACT
Objective 
Mannose-binding lectin (MBL) is important in the innate immune response. MBL2 gene 
polymorphisms aff ect MBL expression, and genotypes yielding low MBL levels have 
been associated with an elevated risk for infections in hematological cancer patients 
undergoing chemotherapy. However, these reported associations are inconsistent, and 
data on patients with solid tumors are lacking. Here, we investigated the eff ects of MBL2 
genotypes on irinotecan-induced febrile neutropenia in patients with solid tumors.
Patients and methods 
Irinotecan-treated patients were genotyped for the MBL2 gene. Two promoter (-550 H/L 
and -221 X/Y) and three exon polymorphisms (52 A/D, 54 A/B, and 57 A/C) were deter-
mined, together with known risk factors for irinotecan-induced toxicity. Neutropenia 
and febrile neutropenia were recorded during the fi rst course.
Results 
Of the 133 patients, 28% experienced severe neutropenia and 10% experienced febrile 
neutropenia. No associations were found between exon polymorphisms and febrile 
neutropenia. However, patients with the H/H promoter genotype, associated with high 
MBL levels, experienced signifi cantly more febrile neutropenia than patients with the 
H/L and L/L genotypes (20% versus 13% versus 5%). Moreover, patients with the HYA 
haplotype encountered signifi cantly more febrile neutropenia than patients without 
this high MBL-producing haplotype (16% versus 4%). In the subgroup with wild-type 
exon polymorphisms (A/A), patients with the high MBL promoter phenotype had the 
highest incidence of febrile neutropenia, regardless of known risk factors.
Conclusion 
Patients with high MBL2 promoter genotypes and haplotypes seem more at risk for 
developing febrile neutropenia. If confi rmed, these preliminary fi ndings may contribute 
to more individualized approaches of irinotecan treatment.
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INTRODUCTION
Mannose-binding lectin (MBL) is produced in the liver and plays an important role in 
the innate immune system.1-3 As a member of the collectin family, MBL possesses a 
carbohydrate recognition domain, which recognizes and binds microbial surface car-
bohydrates.4 A wide range of Gram-positive and Gram-negative bacteria, viruses, fungi, 
and protozoa can be bound by MBL, mediating opsonophagocytosis directly and indi-
rectly by activation of the lectin complement pathway.1,5 Especially when the adaptive 
immune system is immature or compromised, MBL becomes very important. In these 
instances, the innate immune response forms the principal defense against infection, 
thereby theoretically rendering MBL defi ciency a serious risk factor for infection.1 This 
seems particularly relevant when a patient is under immunosuppressive therapy or is 
receiving a bone marrow transplant and/or chemotherapy for hematological malignan-
cies.3,6-11 However, research on the eff ects of MBL on hematological malignancies has 
yielded confl icting results.7,12-16
Five diff erent polymorphisms in the MBL2 gene, located on chromosome 10, are 
related to serum MBL protein levels.17-20 Two promoter polymorphisms, -550 H/L 
(rs11003125) and -221 X/Y (rs7096206), together form three haplotypes, which result in 
high (HY), intermediate (LY), and low (LX) MBL levels (Table 1).18,21 The remaining three 
polymorphisms, also referred to as exon polymorphisms, are located on the fi rst exon 
of the MBL2 gene; codon 52 (Arg→Cys, rs5030737; also known as the MBL2-D variant 
allele), codon 54 (Gly→Asp, rs1800450; also known as the MBL2-B variant allele), and 
Table 1. Overview of MBL2 polymorphisms and haplotype-related expression of MBL
Genotype Phenotype
Exon 1 polymorphism
 A/A High MBL
 A/Oa Intermediate MBL
 O/Oa Low MBL
Promoter haplotypeb
 HY High MBL
 LY Intermediate MBL
 LX Low MBL
Promoter phenotype in A/A patients
 HY/HY and HY/LY High MBL
 LY/LY and HY/LX Medium MBL
 LY/LX and LX/LX Low MBL
Abbreviations: MBL, mannose-binding lectin.
a ‘O’ refers to ‘D’ (52Arg→Cys), ‘B’ (54Gly→Asp), or ‘C’ (57Gly→Glu) MBL2 variants.
b The HX genotype has only been described in three Sub-saharians and has not been demonstrated in 
whites.39,40
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codon 57 (Gly→Glu, rs1800451; also known as the MBL2-C variant allele). Homozygous 
wild-type patients for each of these exon polymorphisms are referred to as A/A and have 
high circulating MBL levels.22 Patients carrying one variant allele have intermediate MBL 
levels and are referred to as A/O, in which the “O” stands for one of the MBL2 variants 
(D, B, or C). Patients carrying two variant alleles, whether two equal or two diff erent 
variants, are referred to as O/O and have low functional MBL levels.22 The occurrence of 
these variants is rather frequent, with approximately 40% of whites bearing at least one 
variant exon polymorphism resulting in reduced serum MBL levels.21,23,24
Irinotecan, a prodrug of the topoisomerase I inhibitor SN-38, is widely used in pa-
tients with colorectal cancer. It is typically known for its unpredictable toxicities, mainly 
consisting of (febrile) neutropenia and late-onset diarrhea. The occurrence of these 
side eff ects may lead to dose reductions or even treatment discontinuation, thereby 
attenuating the antitumor activity of irinotecan.25,26 Several inherited and environmental 
factors aff ect the occurrence of these adverse eff ects. These include polymorphisms in 
genes encoding drug-metabolizing enzymes and transport proteins, lifestyle factors 
such as smoking habits, renal function, and co-medication.27-31 However, despite the 
elucidation of these risk factors, there is an obvious need to get more insight into fac-
tors rendering patients at risk for developing irinotecan-induced toxicities, in particular, 
febrile neutropenia. 
Therefore, together with the facts that data on the association of MBL2 genotypes 
with the occurrence of febrile neutropenia in hematological cancer patients are incon-
sistent and data on such an association in solid cancer patients are lacking, we explored 
the eff ect of MBL2 polymorphisms on febrile neutropenia in irinotecan-treated patients.
PATIENTS AND METHODS
Patients and treatment
Patients who were treated with single agent irinotecan once every three weeks over 90 
minutes at a dose of 350 mg/m2, its 600 mg fl at-fi xed (irrespective of BSA) dose equiva-
lent,32,33 or at a dose that was based on cytochrome P450 (CYP)3A4 phenotyping,34 were 
studied during their fi rst treatment course. Premedication consisted of dexamethasone 
and granisetron. In cases of acute cholinergic syndrome, atropine was administered sub-
cutaneously. Delayed-type diarrhea was treated with loperamide and, if necessary, with 
antibiotics, at the discretion of the treating physician. Febrile neutropenia was treated 
with the broad-spectrum antibiotic imipenem.
All patients had participated in four prospective trials involving pharmacokinetic and 
pharmacodynamic analyses.34-37 Those trials were approved by the institutional medical 
ethical boards of the participating medical centers and were performed in accordance 
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with the Declaration of Helsinki. All patients gave written informed consent for partici-
pation in those studies and for additional pharmacogenetic analyses. The most impor-
tant inclusion criteria of these studies were: a histologically or cytologically confi rmed 
diagnosis of any solid tumor that was believed to be sensitive to irinotecan treatment; 
age ≥ 18 years; a World Health Organization performance status score < 2; and adequate 
hematological, renal, and hepatic function. Additionally, the time between the last 
anticancer treatment and the start of irinotecan treatment had to be > 4 weeks. Further-
more, the use of any known CYP3A and/or P-glycoprotein inhibitor or inducer during 
the whole study period (starting two weeks before the fi rst irinotecan administration) 
was not allowed. Patients with unresolved bowel obstruction or chronic colic disease 
were excluded from the study.
In one of the four studies, some of the patients were prophylactically treated with 
neomycin.35 Because this aminoglycoside antibiotic is poorly absorbed,38 and in this 
study no eff ects of neomycin prophylaxis on the systemic clearance of SN-38 and the 
incidence of serious neutropenia and leukopenia were noted,35 no eff ect of neomycin 
co-treatment on febrile neutropenia was anticipated.
Toxicities
Before the start of irinotecan treatment, a complete medical history, physical examina-
tion, and hematological and chemical blood analyses were performed. During the three-
week follow-up period after the fi rst administration of irinotecan, patients were seen 
weekly at the outpatient clinic for follow-up, which included a physical examination 
and routine hematological, renal, and hepatic laboratory analyses. When patients were 
admitted to the hospital because of severe toxicities, laboratory tests were performed 
more frequently (at least thrice a week). Toxicities were graded according to the Com-
mon Terminology Criteria for Adverse Events version 3.0 of the National Cancer Institute. 
Febrile neutropenia was defi ned as a neutrophil count ≤ 1.0 ×109/mL in the presence 
of fever. Fever was defi ned as a temperature > 38.5°C on a single measurement or a 
temperature > 38.0°C on two separate occasions.9,13
Genotyping
DNA was obtained from whole blood as described previously,37 and samples were 
genotyped for polymorphisms in the MBL2 gene. Five common polymorphisms of the 
MBL2 gene – two in the promoter region (-550 H/L and -221 X/Y) and three in the fi rst 
exon (52 A/D, 54 A/B, and 57 A/C – were analyzed by allele-specifi c amplifi cation reac-
tions, according to Mullighan et al.39 The polymerase chain reaction (PCR) amplifi cation 
was performed in a 25-μL reaction volume, containing 15 ng genomic DNA, PCR Buff er 
II (Perkin Elmer, Waltham, MA), 1.5 mM MgCl2, 0.2 mM of each of the deoxynucleotide 
triphosphates (Roche, Indianapolis, IN), 0.5 U Amplitaq Gold (Perkin Elmer), and 20 pmol 
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of each of the primers, as described elsewhere.39 PCR products were analyzed on a 1% 
agarose gel with ethidium bromide, and results were archived using a Gel Doc GD 2000 
system (Bio-Rad, Hercules, CA).
Construction of MBL2 haplotypes and phenotypes
The two promoter polymorphisms, -550 H/L and -221 X/Y, were combined to form three 
promoter haplotypes: HY, LY, and LX,12 which are related to high, intermediate, and low 
levels of MBL, respectively (Table 1).18,21 The HX haplotype probably does not occur 
in whites because of linkage disequilibrium.39,40 Combination of these haplotypes in 
patients having the wild-type exon genotype (A/A) yielded three MBL2 promoter pheno-
types: high (HY/HY and HY/LY), medium (HY/LX and LY/LY), and low (LY/LX and LX/LX).
Additional analyses
Pharmacokinetic analyses and parameters of irinotecan and the active metabolite SN-
38, as well as the presence of UGT1A1*28 and UGT1A1*93 (-3156 G>A) alleles, which are 
known to infl uence irinotecan pharmacokinetics and toxicities by decreasing glucuroni-
dation,30,41 were determined as described previously.37
Statistical analyses
All exploratory analyses were performed anonymously and without awareness of clini-
cal outcome to exclude any form of potential bias. Diff erences in the incidence of febrile 
neutropenia among exon polymorphisms (A/A, A/O, O/O), promoter polymorphisms 
(-550 H/H, H/L, L/L and -221 X/X, X/Y, Y/Y), and promoter phenotypes (high, medium, 
low) were analyzed using χ2-tests for trends. 
Associations between toxicities and the presence or absence of the HYA and LXA 
haplotypes were analyzed using χ2-tests. In addition, odds ratios (ORs) with 95% con-
fi dence intervals (CIs) were calculated. Diff erences in patient characteristics among the 
MBL-phenotype groups and the promoter polymorphism and haplotype groups were 
analyzed using Kruskal-Wallis tests in cases of continuous variables and χ2-tests (for 
trends) in cases of nominal variables. 
Statistical calculations were performed using SPSS version 16.0 (SPSS Inc., Chicago, 
IL). P-values < .05 were considered signifi cant.
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RESULTS
Patient characteristics
One hundred thirty-three patients were successfully genotyped for MBL2 and were in-
cluded in the analyses. Thirteen patients were excluded from the analyses because there 
was no blood available for genotyping (N = 7), MBL genotype could not be obtained 
(N = 4), or no toxicity data were available (N = 2). The characteristics of these patients 
are shown in Table 2. Seventy-two patients (54%) were male and 61 patients (46%) were 
female. Ninety-seven percent of the patients were white. The most common tumor 
types were colorectal cancer (27%), upper gastrointestinal cancer (15%), and (adeno)
carcinoma of unknown primary (15%). Nineteen patients (15%) had been prophylacti-
cally treated with neomycin, as mentioned before.35
Toxicities
Twenty-nine patients (22%) experienced fever during their fi rst irinotecan course. 
Twenty patients (15%) had grade 3 neutropenia and 17 patients (13%) experienced 
grade 4 neutropenia. Febrile neutropenia was seen in 13 patients (10%) and lasted a 
median of 1.5 days (range, 1-4 days). In 11 patients with febrile neutropenia (85%), there 
were neither positive blood cultures nor any clinical signs of infection other than fever. 
In the only two positive blood cultures that were found, one showed Escherichia coli and 
the other showed Pseudomonas aeruginosa. No eff ect of co-treatment with neomycin 
on the incidence of febrile neutropenia was seen in this study. Of the 19 patients who 
received neomycin, 3 developed febrile neutropenia (16%), whereas in patients who 
were not treated with neomycin, 9 of 102 (8%) developed febrile neutropenia (P = .285).
MBL2 polymorphism frequencies
In four patients (2.9%), MBL2 genotyping was not successful, and therefore those patients 
were excluded from the analyses. In line with recent publications,8,14 50 patients (38%) 
carried at least one exon 1 mutation. The allele frequency of the wild-type allele (A) was 
78%, whereas the rest of the alleles were variably present, with allele frequencies of 5%, 
15%, and 2% for the D, B, and C variants, respectively. The frequencies of the -550H and 
-550L alleles in the promoter were 32% and 68%, respectively, and the frequencies of the 
-221X and -221Y promoter alleles were 22% and 78%, respectively. 
Combining the promoter and exon 1 polymorphisms, six haplotypes were found 
based on the genotyping results and available literature.18,39 The most frequent hap-
lotypes were LYA, HYA, and LXA, with haplotype frequencies of 20-30%, whereas LYC 
and HYD were found sporadically, with haplotype frequencies < 5%. The haplotype fre-
quency of LYB was 15%. These frequencies were in accordance with previously reported 
frequencies in whites.8,14,24,42,43
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Table 2. Patient characteristics
Characteristica N % or range
Age (years)b 57 27-74
BSA (m2)b 1.90 1.35-2.50
Race
 White 129 97%
 Otherc 4 3%
Sex
 Male 72 54%
 Female 61 46%
Tumor type
 Colorectal 36 27%
 Upper gastrointestinal tract 20 15%
 (A)CUP 20 15%
 Lower gastrointestinal tractd 18 14%
 Lung 15 11%
 Sarcoma 8 6%
 Othere 16 12%
UGT1A1*28f
 TA6/TA6 (wild-type)g 59 44%
 TA6/TA7h 63 47%
 TA7/TA7i 8 6%
UGT1A1*93 (-3156G>A)f
 G/G (wild-type) 64 49%
 G/A 58 45%
 A/A 8 6%
Abbreviations: (A)CUP, (adeno)carcinoma of unknown primary; BSA, body surface area.
a Data are presented as numbers with percentages, unless stated otherwise.
b Data are presented as median with range.
c Including Asian (N = 1) and Afro-Caribbean (N = 3).
d Including cancer of the bile tract (pancreatic cancer, cholangiocarcinoma, gall bladder cancer, ampulla of 
vater carcinoma) and small intestines, excluding colorectal cancer.
e Including breast cancer (N = 4), head and neck cancer (N = 3), cervical carcinoma (N = 3), ocular 
melanoma (N = 2), urothelial cell carcinoma (N = 2), ovarian carcinoma (N = 1), and medulloblastoma 
(N = 1).
f N = 130 (UGT1A1*28 and UGT1A1*93 status could not be obtained in three patients).
g All patients who were homozygous for the wild-type *28 allele were also homozygous for the wild-type 
*93 allele.
h Fifty-eight of 63 heterozygous *28 patients (TA6/TA7) were also heterozygous for the *93 variant allele. 
Five TA6/TA7 patients were homozygous for the wild-type *93 allele (G/G).
i All patients who were homozygous for the variant *28 allele were also homozygous for the variant *93 
allele.
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MBL2 exon polymorphisms in relation to irinotecan-induced febrile neutropenia
Febrile neutropenia was not signifi cantly associated with the presence of a certain 
exon polymorphism (Table 3). The incidences of febrile neutropenia were 8% (7 of 83 
patients) in patients with the A/A genotype, 15% (6 of 41 patients) in patients with the 
A/O genotype, and 0% (0 of 8 patients) in the O/O patients (P = .853). In the subgroup 
of patients with severe (grade 3 or 4) neutropenia, no relation was found between the 
incidence of fever and the presence of a certain exon polymorphism.
Table 3. MBL2 polymorphisms and haplotypes in relation to irinotecan-induced toxicities
Polymorphisms and haplotypes Febrile neutropeniaa Severe (grade 3 or 4) neutropeniaa
Yes No Yes No
N % N % Pb N % N % Pb
Exon 1 polymorphism .853 .175
 A/A 7 8% 76 92% 25 30% 57 70%
 A/O 6 15% 35 85% 12 29% 30 71%
 O/O 0 0% 8 100% 0 0% 8 100%
-550 promoter polymorphism (H/L) .039 .437
 H/H 3 20% 12 80% 6 40% 9 60%
 H/L 7 13% 46 87% 14 26% 39 74%
 L/L 3 5% 61 95% 17 27% 47 73%
-221 promoter polymorphism (X/Y) .079 .869
 X/X 0 0% 10 100% 3 30% 7 70%
 X/Y 2 5% 37 95% 10 26% 29 74%
 Y/Y 11 13% 72 87% 24 29% 59 71%
HYA haplotype .019c .396c
 Present 10 16% 51 84% 19 32% 41 68%
 Absent 3 4% 68 96% 18 25% 54 75%
LXA haplotype .088c .768c
 Present 2 4% 47 96% 13 27% 36 73%
 Absent 11 13% 72 87% 24 29% 59 71%
Promoter phenotype in 
exon 1 wildtype patients (A/A)d
.030 .687
 High (HY/HY and HY/LY) 6 15% 33 85% 13 34% 25 66%
 Medium (LY/LY and HY/LX) 1 5% 20 95% 5 24% 16 76%
 Low (LY/LX and LX/LX) 0 0% 23 100% 7 30% 16 70%
a N = 132 patients (data on febrile neutropenia missing in one patient, data on severe neutropenia missing 
in another patient).
b P-value result from χ2-test for trend, unless stated otherwise.
c P-value result from χ2-test.
d N = 83 patients.
Jessica van der Bol bw.indd   49 29-04-11   15:31
50 Chapter 3
A
B
C
Figure 1. Bar graphs showing the eff ects of the MBL2-promoter -550H/L polymorphism (A), MBL2-
promoter -221X/Y polymorphism (B), and MBL2-promoter phenotypes (high, HY/HY and HY/LY; medium, 
LY/LY and HY/LX; and low, LY/LX and LX/LX) in patients with the wild-type exon polymorphism (A/A) (C) 
on the incidence of febrile neutropenia in cancer patients treated with irinotecan.
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MBL2 promoter polymorphisms in relation to irinotecan-induced febrile neutropenia
As illustrated in Figure 1A and Table 3, patients with the H/H genotype had a higher 
incidence of febrile neutropenia than patients with the H/L and L/L genotype (3 of 15 
patients (20%) versus 7 of 53 patients (13%) versus 3 of 64 patients (5%); P = .039). A 
higher incidence of febrile neutropenia was also observed in patients carrying the Y/Y 
genotype than in those carrying the X/Y and X/X genotypes (11 of 83 patients (13%) 
versus 2 of 39 patients (5%) versus 0 of 10 patients (0%)) (Figure 1B), although this fi nd-
ing did not reach statistical signifi cance (P = .079). In both analyses, the diff erences in 
the incidence of febrile neutropenia could not be explained by a diff erent incidence of 
severe (grade 3 or 4) neutropenia in the groups (P = .437).
Similarly, in patients experiencing severe neutropenia, the risk for febrile neutropenia 
was likewise dependent on promoter genotype, illustrating the role of MBL in immune-
compromised patients. Patients with the H/H and the H/L genotypes had higher 
incidences of febrile neutropenia than patients with the L/L genotype (50% versus 50% 
versus 18%; P = .066), and patients carrying the Y/Y genotype had a higher incidence of 
febrile neutropenia than patients carrying the X/Y and X/X genotypes (48% versus 20% 
versus 0%; P = .044).
MBL2 promoter haplotypes and phenotypes in relation to irinotecan-induced febrile neutropenia
In line with analyses of individual promoter polymorphisms, patients with at least one 
HYA haplotype had a four times higher incidence of febrile neutropenia than patients 
who did not have this high MBL level haplotype (16% versus 4%; OR, 4.4; 95% CI, 1.2-17.0; 
P = .019) (Figure 2A). In the subgroup of patients with a wild-type exon polymorphism 
(A/A), patients with the HYA haplotype also had a higher incidence of febrile neutrope-
nia (N = 83; 15% versus 0%; OR, 1.2; 95% CI, 1.0-1.3; P = .018). Importantly, in patients with 
severe neutropenia (grade 3 or 4), the presence of at least one HYA haplotype resulted 
in a higher risk for developing fever during the neutropenic episode (N = 36; 53% versus 
18%; OR, 5.2; 95% CI, 1.1-24.1; P = .029). This was also the case in the subgroup of patients 
with the wild type exon polymorphism who had severe neutropenia (N = 25; 47% versus 
0%; OR, 1.9; 95% CI, 1.2-3.0; P = .011).
Although not signifi cant, patients without the low MBL-producing haplotype LXA had 
a trend toward a more than three times higher risk for febrile neutropenia than patients 
with this haplotype (13% versus 4%; OR, 3.6; 95% CI, 0.8-16.9; P = .088) (Figure 2B). 
In the subgroup of patients with the wild-type exon polymorphism (A/A), patients 
with the high MBL2 promoter phenotype (HY/HY and HY/LY) had the highest incidence 
of febrile neutropenia, compared with the medium (LY/LY and HY/LX) and low (LY/LX 
and LX/LX) MBL2 promoter phenotypes, as illustrated in Figure 1C (15% versus 5% versus 
0%; P = .030). This could not be explained by a higher incidence of severe (grade 3 or 
4) neutropenia in this group (34% versus 24% versus 30%; P = .687). Likewise, no eff ect 
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of other potential confounders such as age, exposure to SN-38, or the presence of the 
UGT1A1*28 or UGT1A1*93 alleles was found (Tables 4-6).
Also, in the subgroup of patients with the wild-type exon polymorphism who expe-
rienced severe neutropenia, a higher incidence of febrile neutropenia was observed in 
patients with the high MBL2 promoter phenotypes (46% versus 20% versus 0%; P = .029).
A
B
Figure 2. Bar graphs showing the negative eff ects of the presence of at least one MBL2 HYA haplotype (A) 
and the absence of a MBL2 LXA haplotype (B) on the incidence of febrile neutropenia in cancer patients 
treated with single agent irinotecan.
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DISCUSSION
This study explored the infl uence of MBL2 polymorphisms on chemotherapy-induced 
neutropenic fever in adult cancer patients with solid tumors. Because the innate immune 
response, with MBL as a key factor, is thought to play a crucial role in the defense against 
infectious pathogens (in particular, in cases of neutropenia), we initially hypothesized 
that patients with functional genotypes associated with low MBL production would be 
more prone to develop neutropenic fever. In contrast, we found that patients with high 
MBL-producing promoter genotypes, haplotypes, and haplotype combinations of the 
MBL2 gene suff er more often from febrile neutropenia after irinotecan chemotherapy 
Table 4. Distribution of other variables in patients with the -550 H/L MBL2 promoter polymorphism 
Variablea H/H H/L L/L Pb
Irinotecan dose (mg) 680 600 600 .554
Irinotecan AUC0-100h (mg×h/L) 21.4 20.5 21.9 .706
SN-38 AUC0-100h (ng×h/mL) 451.5 488.3 482.9 .932
UGT1A1*28 genotypingc .329d
 No *28 allele 11 (19%) 19 (32%) 29 (49%)
 ≥ 1 *28 allele 4 (6%) 33 (46%) 34 (48%)
UGT1A1*93 genotypingc .676d
 No *93 allele 11 (17%) 20 (31%) 33 (52%)
 ≥ 1 *93 allele 4 (6%) 32 (48%) 30 (45%)
a Data are presented as medians, unless stated otherwise. 
b Kruskal-Wallis test, unless stated otherwise. 
c Data are presented as numbers with percentages in parentheses.
d Chi-square test for trend.
Table 5. Distribution of other variables in patients with and without the HYA haplotype 
Variablea HYA+ HYA- Pb
Irinotecan dose (mg) 620 600 .223
Irinotecan AUC0-100h (mg×h/L) 20.5 21.9 .306
SN-38 AUC0-100h (ng×h/mL) 483.9 449.2 .190
UGT1A1*28 genotypingc .935d
 No *28 allele 27 (46%) 32 (54%)
 ≥ 1 *28 allele 33 (46%) 38 (54%)
UGT1A1*93 genotypingc .588d
 No *93 allele 28 (44%) 36 (56%)
 ≥ 1 *93 allele 32 (48%) 34 (52%)
a Data are presented as medians, unless stated otherwise. 
b Kruskal-Wallis test, unless stated otherwise. 
c Data are presented as numbers with percentages in parentheses.
d Chi-square test.
Jessica van der Bol bw.indd   53 29-04-11   15:31
54 Chapter 3
than patients with low MBL-producing genotypes. Also, in the group of patients who 
developed grade 3 or 4 neutropenia, the incidence of neutropenic fever was higher in 
patients with genotypes yielding high MBL levels.
In view of our results, we hypothesize that low MBL levels (as determined by genotype) 
might have a protective eff ect against the occurrence of fever in neutropenic patients 
because of insuffi  cient activation of the complement system. A high frequency of unex-
plained fever during neutropenic episodes was shown previously.44,45 Also, in our study 
population, almost no infectious causes could be identifi ed in the patients developing 
febrile neutropenia. Therefore, it could be hypothesized that fever in (most) patients 
with neutropenia is induced by the neutropenic state as such, rather than by the pres-
ence of infectious pathogens. This might explain why patients with high MBL genotypes 
had a higher incidence of febrile neutropenia in our study, because higher MBL levels 
might induce the occurrence of an immunological response.46 Another explanation for 
our fi ndings is that transient neutropenia is commonly associated with subclinical infec-
tions. If true, those patients with genotypes yielding high MBL levels may be more prone 
to developing fever as a response to neutropenia than patients with genotypes yielding 
low MBL concentrations. However, these explanations are hypothetical and should be 
further investigated.
To the best of our knowledge, this is the fi rst study addressing the association of 
MBL genotypes and neutropenic fever in adult patients with solid malignancies who are 
treated with chemotherapy. Previous research on the infl uence of MBL2 polymorphisms 
and MBL serum levels on the incidence and duration of infectious toxicities has been 
conducted only in hematological and pediatric cancer patients, and yielded confl icting 
Tabel 6. Distribution of other variables in MBL2 promoter phenotype groups in the exon polymorphism 
wild-type (A/A) patients (N=83) 
Variablea High Medium Low Pb
HY/HY and HY/LY LY/LY and HY/LX LY/LX and LX/LX
Irinotecan dose (mg) 620 600 610 .736
Irinotecan AUC0-100h (mg×h/L) 20.0 21.3 21.7 .901
SN-38 AUC0-100h (ng×h/mL) 498.7 424.7 492.6 .278
UGT1A1*28 genotypingc .855d
No *28 allele 18 (47%) 9 (43%) 10 (45%)
≥ 1 *28 allele 20 (53%) 12 (57%) 12 (55%)
UGT1A1*93 genotypingc .938d
No *93 allele 19 (50%) 9 (43%) 11 (50%)
≥ 1 *93 allele 19 (50%) 12 (57%) 11 (50%)
a Data are presented as medians, unless stated otherwise. 
b Kruskal-Wallis test, unless stated otherwise. 
c Data are presented as numbers with percentages in parentheses.
d Chi-square test for trend.
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results. In patients with genotypes producing low MBL levels, a longer duration of febrile 
neutropenia and a higher risk for major infections were reported in pediatric patients 
undergoing chemotherapy for (mainly) hematological malignancies and in adults after 
allogeneic hemopoietic stem cell transplantation.7,9 The diff erences between these 
and our results may be explained by the, in general, much more myelosuppressive (or 
even myeloablative) eff ect of chemotherapy for hematological malignancies than of 
chemotherapy administered to our population, apart from the fact that hematological 
malignancies themselves also cause myelosuppression,47 and that the mode of action of 
MBL is infl uenced by the depth and duration of myelosuppression. 
In line with our fi ndings, Schlapbach et al. found that not only children with the 
lowest MBL levels (< 100 μg/L), but also children with the highest MBL levels (> 1,000 
μg/L) had more frequent episodes of febrile neutropenia and were hospitalized longer 
than children with intermediate MBL levels after chemotherapeutic treatment for solid 
and hematological cancers.10 They showed that high MBL levels may be less benefi cial 
for patients, possibly as a result of greater complement activation and the stimulation 
of pro-infl ammatory signals,46 and that moderate MBL defi ciency may be favorable, 
especially in patients who briefl y receive immunosuppressive chemotherapy. This could 
explain why we only found an eff ect of promoter polymorphisms, which are known to 
have a less dramatic eff ect on MBL levels than exon polymorphisms, on the incidence of 
febrile neutropenia.18 Another interesting analysis showed a trend toward more grade 4 
neutropenic infections in multiple myeloma patients carrying the high MBL-producing 
wild-type exon polymorphism.14 Interestingly, Klostergaard et al. found a signifi cantly 
higher incidence of Gram-negative blood cultures in high MBL genotypes,48 which could 
explain why we found a higher incidence of febrile neutropenia in high MBL genotypes 
and positive blood cultures of only Gram-negative bacteria (Escherichia coli and Pseudo-
monas aeruginosa) in our study.
In addition to these studies, several other studies could not reveal an association 
between MBL2 genotype or serum MBL levels and infectious complications after 
chemotherapy.12,13,16,49 The confl icting outcomes of these studies clearly underline that 
more research is required to unravel the exact relationship among MBL2 genotypes, 
MBL serum levels, and the occurrence of neutropenic events in cancer patients treated 
with chemotherapy. We therefore feel that the initiation of studies on MBL replacement 
therapy, as has occurred in patients with multiple myeloma or children with chemother-
apy-induced neutropenia, is premature.50
An important caveat of studies on the relationship between MBL2 gene polymor-
phisms and neutropenic events (including ours) is the fact that in ill people, MBL levels 
are determined not only by genotype, but likely also by the disease itself in the context 
of an acute-phase response.8,12,13 Moreover, our study population was relatively small, 
which resulted in a low absolute number of neutropenic events seen. In addition, sev-
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eral tumor types were involved, which could have infl uenced outcomes. Because this 
study was exploratory in nature, no corrections for multiple analyses were performed. 
Therefore, our fi ndings should be interpreted with caution and should be confi rmed in 
larger (and more uniform) study populations, preferably in combination with MBL serum 
level measurements, to determine whether the known genotype/phenotype relations 
in healthy humans are comparable in cancer patients. If confi rmed, the fi nding that 
patients having polymorphisms in the MBL2 gene, associated with high MBL levels, have 
an elevated risk for developing irinotecan-induced febrile neutropenia is of importance. 
As a result, MBL2 genotyping could have a meaningful place in clinical decision making 
and contribute to more personalized patient management.
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ABSTRACT
Although approximately half of the administered dose of irinotecan is recovered in 
urine, scarce data are available on the association of renal function with irinotecan 
pharmacokinetics and toxicity. Here, these relationships are investigated in 187 patients 
treated with irinotecan in a three-weekly schedule. No signifi cant eff ects on irinotecan 
pharmacokinetics were found in these patients. However, in 131 patients treated with 
the registered dose, categorized renal function was related to hematological toxicity. 
The incidence of grade 3-4 neutropenia decreased as function of creatinine clearance, 
particularly in non-smoking patients (P < .01). Patients with lower creatinine clearances 
(35-66 mL/min) had a four times higher risk of grade 3-4 neutropenia (58% versus 14%; 
P < .001). This study suggests that pretreatment renal function values are associated 
with irinotecan-induced neutropenia. A confi rmatory analysis is warranted to determine 
whether measures of renal function should be incorporated in future attempts toward 
individualized treatment with irinotecan.
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INTRODUCTION
Irinotecan is an anticancer drug used in the treatment of various types of cancers. Added 
to fl uorouracil, it has become (part of ) the standard of care in colorectal cancer.1,2 Like 
other anticancer drugs, a narrow therapeutic window characterizes this topoisomerase-
I inhibitor, with delayed-type diarrhea and neutropenia being the main dose-limiting 
toxicities.3-5 Indeed, occurrence of these toxicities has been directly related to the ex-
posure to its active metabolite SN-38 (7-ethyl-10-hydroxycamptothecin). After the view 
emerged that dose-individualization based on body surface area (BSA) does not truly 
personalize irinotecan treatment,6,7 numerous other potential determinants have been 
investigated. 
The ultimate goal of these attempts is to predict the individual patient’s drug clear-
ance before administration of irinotecan to calculate a patient-tailored dose resulting 
in a controlled, predictable, and safe systemic exposure. For example, genetic polymor-
phisms in the uridine diphosphate glucuronosyltransferase (UGT) genes are known 
to result in a reduced detoxifi cation capacity of SN-38 into its glucuronide conjugate 
(SN-38G) and thus in a higher systemic exposure to toxic SN-38. In particular, the homo-
zygous presence of an additional, seventh, TA-repeat in the promoter region of UGT1A1 
(TA7; UGT1A1*28) has been identifi ed as a risk factor for therapy-induced neutropenia.4,8
Cytochrome P450 (CYP) 3A activity also relates to irinotecan interpatient variability. 
Apart from drug-drug interactions on the CYP3A level resulting in unintended toxicity 
or undertreatment,9 a high correlation between the clearance of irinotecan and the 
CYP3A phenotyping probe midazolam has been demonstrated,10 based on which a 
new dosing formula truly personalizing irinotecan treatment has been derived, which 
is currently being tested prospectively. Lifestyle behavior may aff ect irinotecan therapy 
as well, making it a factor that should be kept in mind while considering the application 
of or actually dosing irinotecan. Recently we showed that cigarette smoke constituents 
induce key enzymes and transporters involved in irinotecan metabolism, resulting in a 
signifi cantly reduced exposure to SN-38 and a reduction in National Cancer Institute’s 
Common Terminology Criteria (version 3.0) grade 3-4 neutropenia from 38 to 6%.11
For those cytotoxic agents for which renal excretion plays a major role in its elimina-
tion pathways, drug pharmacokinetics may be altered in patients with impaired renal 
function. Although recently questioned for patients with adequate renal function,12 
carboplatin, for example, is routinely tailored to a patient’s renal function according to 
Calvert’s formula. Based on this formula, carboplatin dosing is adjusted to an expected 
exposure given a patient’s renal function, defi ned as the creatinine clearance, which is 
supposed to avoid excessive exposure and toxicity, as well as too low exposure related to 
reduced therapeutic benefi t,12,13 thus optimizing treatment outcome. Likewise, depend-
ing on the drug and the severity of renal impairment in patients with impaired renal 
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function, dose adjustment should be considered for anticancer drugs such as cisplatin, 
epirubicin, cyclophosphamide, etoposide, and capecitabine, among others.14
In mass balance studies on irinotecan more than half of the dose recovered was found 
in urine, with unchanged irinotecan, the inactive metabolite APC (7-ethyl-10-[4-N-(5 
aminopentanoic acid)-1-piperidino]-carbonyloxy-camptothecin), and the glucuronide 
conjugate of SN-38 (Figure 1) as the main excretion products in urine.15-17 Despite the 
signifi cant renal involvement in the excretion of irinotecan, most attention has been 
focused on hepatic and intestinal factors explaining interpatient variability in pharma-
cokinetics and toxicity. In addition, data on the pharmacokinetics of irinotecan in renally 
impaired patients are scant.14,18 A single previous study showed that renal impairment 
did not alter irinotecan pharmacokinetics, although the number of studied patients 
was very small.18 Because irinotecan was administered at a reduced dose of 225 mg/
m2 to only nine patients with varying degrees of renal impairment (median creatinine 
clearance of 41 mL/min; range 21-60 mL/min), it was not possible to provide a dosing 
recommendation. 
In this study, we retrospectively assessed in prospectively obtained data the associa-
tions of renal function with irinotecan pharmacokinetics and toxicity in a large cohort of 
cancer patients to investigate whether renal function can be a valuable addition in the 
toolbox to individualize irinotecan therapy.
Irinotecan 
SN-38 
Inactive metabolites 
(APC/NPC/M4) 
SN-38G 
                        CYP3A4/5 
 
 
 
 
           CES      
       CES           
 
 
      
 
      Intestinal             UGT1A1/7/9 
E-glucuronidase             
 
 
 
 
Figure 1. Metabolism of irinotecan
Irinotecan is metabolized into its active metabolite SN-38 by carboxylesterases (CES). SN-38 (7-ethyl-10-
hydroxycamptothecin) is subsequently inactivated into its glucuronide conjugate, SN-38G, by uridine 
diphosphate glucuronosyltransferases (UGTs), especially by UGT1A1, 1A7, and 1A9, in decreasing 
order of importance. After hepatobiliary excretion, SN-38G can be reconverted into active SN-38 by 
β-glucuronidases, produced by intestinal bacteria. An alternative pathway of irinotecan detoxifi cation is 
the CYP3A (cytochrome P450 isoforms 3A4 and 3A5)-mediated oxidation of irinotecan in APC (7-ethyl-10-
[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-
piperidino]-carbonyloxycamptothecin). NPC, and possibly APC, can be converted into SN-38 by CES as well.
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METHODS
Patients
Common inclusion criteria for the various trials, including pharmacokinetic analysis of 
irinotecan and its metabolites SN-38 and SN-38G, in which the patients participated 
have been described extensively elsewhere.3,6,10,19-24 Depending on the specifi c study 
protocol, patients with serum creatinine levels on study entry of < 1.25 or 1.5 times the 
institutional upper limit of normal and/or a minimum creatinine clearance calculated 
according to Cockcroft-Gault of 60 mL/min were considered eligible. All trials were 
conducted according to the revised Declaration of Helsinki and were approved by the 
local medical ethical committee and written informed consent was obtained from all 
patients. 
A specifi c exclusion criterion for this study was the use of agents known to interfere 
with the function and transcription of CYP3A or UGT1A. Other study-specifi c criteria 
included the availability of a baseline serum creatinine level, and the availability of 
smoking status, given the previously documented eff ects of smoking on irinotecan 
pharmacokinetics and neutropenia.11 In those patients who had separately consented 
for a genetic procedure, UGT1A1 genotype analysis was performed for the presence 
of an additional (seventh) repeat in its promoter region (i.e., UGT1A1*28) as described 
previously.10 Patients homozygous for six repeats (wild type) were assigned as TA6/TA6, 
patients homozygous for seven repeats (variant) as TA7/TA7, and heterozygous patients 
as TA6/TA7.
Treatment
Irinotecan (Campto/Camptosar; Pfi zer, Capelle aan den IJssel, The Netherlands) was 
administered in a three-weekly schedule using a 90-minute infusion. Doses ranged from 
175 to 350 mg/m2 or 600 mg. One hundred and thirty-one patients were treated with 
350 mg irinotecan per square meter BSA or its 600 mg fl at-fi xed dose equivalent. Pro-
phylactic antiemetics, atropine (in case of an acute cholinergic syndrome), loperamide 
(at the earliest signs of delayed-onset diarrhea), and antibiotics (if loperamide did not 
control diarrhea) were administered as needed.
Pharmacokinetic analysis
Blood samples were collected, handled, and analyzed for irinotecan, SN-38, and SN-
38G, as described previously in detail.25-28 Individual pharmacokinetic parameters were 
derived as empirical Bayes estimates and were predicted using a three-compartment 
population model using the software package NONMEM version V (Globomax, Hanover, 
MD).29 Clearances for irinotecan, SN-38, and SN-38G were calculated, and the area under 
the plasma concentration-time curves (AUC) were simulated up to 100 hours.
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Pharmacodynamic analysis
Complete blood cell counts with diff erential, including white blood cell count and 
absolute neutrophil count, and clinical chemistry data were determined at baseline. 
For inclusion into the toxicity analyses, patients had to be treated with single agent 
irinotecan at the three-weekly registered dose of 350 mg/m2 or its 600 mg fl at-fi xed 
dose equivalent. During a three-week follow-up period, patients were seen weekly in 
the outpatient clinic for toxicity assessment and blood analysis. Toxicities, in particular 
leukopenia, neutropenia, and diarrhea, were graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events version 3.0 and were further 
dichotomized in no/mild (grade 0-2) and severe (grade 3-4) toxicity. In addition, hema-
tological toxicity was evaluated using absolute nadir and percentage decrease at nadir 
from baseline.
Renal function
The creatinine clearance was calculated according to the formula derived by Cockcroft-
Gault (140 – (age in years)) × (weight in kg) × (1 – 0.15 × (gender; 0 if male, 1 if female))/
((serum creatinine in mg/dL) × 72). In clinical practice, several classifi cations are used. 
The FDA, for example, divides renal function into fi ve diff erent groups.30 Group 1 (normal 
function) has an estimated creatinine clearance > 80 mL/min, group 2 (mild impairment) 
between 50 and 80 mL/min, group 3 (moderate impairment) between 30 and 50 mL/
min, group 4 (severe impairment) < 30 mL/min, and group 5 (end stage renal disease) 
those requiring dialysis (Table 1). 
Table 1. Distributions of estimated creatinine clearances over diff erent classifi cationsa
Present study FDA
Boundariesb N % Boundariesb N %
Group 1 > 130 23 12.2% > 80 128 68.4%
Group 2 98-130 65 34.8% 50-80 56 29.9%
Group 3 66-98 68 36.4% 30-50 3 1.6%
Group 4 35-66 31 16.6% < 30c 0 0%
Abbreviations: FDA, US Food and Drug Administration; N, number of patients.
a Creatinine clearance calculated according to Cockcroft-Gault. 
b Boundaries in mL/min.
c Those requiring dialysis are included in a fi fth category.
Also other classifi cation systems with somewhat other boundaries or normalized to 
BSA are used. If renal function is expected to play a role in predicting its pharmacokinet-
ics and/or adverse eff ects, in clinical practice usually a cutoff  value of 60 mL/min is used 
to determine whether a specifi c anticancer agent can be safely administered or not. 
Given the inclusion criteria of the studies in which the patients included in the present 
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analysis participated,3,6,10,19-24 and the clinical irinotecan practice for safety applied lower 
boundaries of renal function, a limited number of patients in groups 2-5 was expected 
(Table 1). Therefore, to investigate the eff ects of renal function on irinotecan pharma-
cokinetics and toxicity adequately, an alternative classifi cation, categorizing creatinine 
clearance in four diff erent groups based on its mean and SD, as shown in Table 2, was 
used.
Table 2. Boundaries of estimated creatinine clearance used in this studya
Lower bound Upper bound Boundaries (mL/min) N
Group 1 mean + SD — > 130 23
Group 2 mean mean + SD 98-130 65
Group 3 mean – SD mean 66-98 68
Group 4 — mean – SD < 66 31
Abbreviations: N, number of patients; SD, standard deviation.
a Creatinine clearance calculated according to Cockcroft-Gault.
Statistical analysis
Data are presented as mean with SD in parentheses, unless stated otherwise. Pearson’s 
correlation coeffi  cient was calculated to evaluate potential relationships between 
continuous variables. In case of two categorical variables, the χ2-test was performed. 
Multiple linear regression analysis was performed to exclude possible confounding ef-
fects of parameters related to creatinine clearance on the relationship between toxicity 
and categorized creatinine clearance. The Student’s t-test or one-way ANOVA was used 
to compare diff erences in continuous variables among diff erent categories of creatinine 
clearance, whereas the Jonckheere-Terpstra test was performed to investigate trends 
over the categorized groups. Correcting for multiple analyses, two-sided probability 
values of < .01 were considered as statistically signifi cant. All tests were performed with 
SPSS version 14.0.0 (SPSS, Chicago, IL).
RESULTS
Patients
A total of 187 patients (Table 3) were evaluable for pharmacokinetic analysis of irinote-
can, SN-38, and SN-38G. About half of patients were male and one in three was classifi ed 
as a (current) smoker. The most common tumor types were colorectal cancer, (adeno)
carcinoma of unknown primary, and lung cancer. One hundred and thirty-one patients 
were treated with the registered dose of irinotecan (350 mg/m2 or 600 mg) and their 
data were available for toxicity analysis.
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4
Renal function
The mean baseline serum creatinine concentration was 80 μmol/L ( 21) and ranged 
from 44 to 151 μmol/L. Creatinine clearance calculated according to Cockcroft-Gault 
was between 35 and 231 mL/min, and based on its mean (98 mL/min) and standard 
deviation (32 mL/min), renal function was categorized in four separate groups (Table 2). 
Group 1 consisted of 23 patients with the highest creatinine clearance (i.e., > 130 mL/
min), group 2 included 65 patients with a creatinine clearance between 98 and 130 mL/
min, group 3 had 68 patients with a creatinine clearance between 66 and 98 mL/min, 
and group 4 involved 31 patients with the lowest creatinine clearance (i.e., between 35 
and 66 mL/min). 
Distribution over the more conventional classifi cation according to the US Food and 
Drug Administration (FDA) is shown in Table 1. Baseline characteristics of all four groups 
are shown in Table 3. Only variables directly related to creatinine clearance (i.e., age, weight, 
height, BSA, and serum creatinine) showed signifi cant diff erences between the four groups 
(P < .01). Importantly, no signifi cant diff erence of smoking prevalence (P = .72) or distribu-
tion of the variant UGT1A1*28 allele (P = .84) were detected among the four groups.
Renal function and irinotecan pharmacokinetics
No signifi cant correlation between renal function and the clearance of irinotecan (ρ = 
.14; P = .05), SN-38 (ρ = .12; P = .12), and SN-38G (ρ = .15; P = .06) was found (Table 4). 
Patients with lower creatinine clearance (between 35 and 66 mL/min) had a 13% lower 
irinotecan clearance (28.5 L/h versus 32.9 L/h; P = .02) than patients with a creatinine 
clearance over 98 mL/min. Clearances of SN-38 and SN-38G did not diff er substantially 
(P > .17). Similarly, in the subgroup of patients treated at the recommended dosage, no 
signifi cant association of creatinine clearance with irinotecan pharmacokinetics (data 
not shown) could be demonstrated, although the clearance of SN-38G in non-smokers 
tended to decrease with categorized creatinine clearance (P = .02), indicating that renal 
function might aff ect irinotecan excretion.
Renal function and irinotecan-related toxicity
In the subgroup of 131 patients treated at a dose of 350 mg/m2 or 600 mg, renal function 
was signifi cantly associated with the occurrence and severity of hematological toxicity, 
in particular with neutropenia (Table 5). Specifi cally, the incidence of grade 3-4 neutro-
penia increased when categorized creatinine clearance worsened. Multivariate analysis 
revealed that none of the demographic factors a priori known to be related to creatinine 
clearance was signifi cantly associated with the occurrence of grade 3-4 neutropenia, 
whereas only creatinine clearance was retained in the model (P < .01). Likewise, control-
ling for these demographic factors, creatinine clearance was the only factor signifi cantly 
related to the nadir in neutrophil count. Patients with a mild-to-moderate impaired renal 
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function (i.e., creatinine clearance between 35 and 66 mL/min) had a 2.5-times higher 
risk on grade 3-4 neutropenia (47.1% versus 18.8%) than patients with a creatinine clear-
ance over 98 mL/min. To be more specifi c, the nadir of the absolute neutrophil count in 
the renally impaired group was one-third lower (1.6 versus 2.5 ×109/L). Similar results 
were found on using the FDA classifi cation. Specifi cally, patients with a mildly impaired 
renal function (i.e., creatinine clearance between 50 and 80 mL/min) had a 2.2-times 
higher risk on grade 3-4 neutropenia (47.2% versus 21.7%; P < .01) than patients with a 
creatinine clearance over 80 mL/min. 
Given the low incidence of neutropenia in smoking patients (6%; Table 5), the eff ects 
of renal function on toxicity were particularly noticeable in the non-smoking group 
(N = 97; Figure 2). In this group, patients with a lower creatinine clearance (i.e., > 1 SD 
below the average creatinine clearance) had a 4.1-times increased risk for grade 3-4 
neutropenia than patients with a high creatinine clearance (i.e., > 1 SD above the aver-
age creatinine clearance). The incidence of grade 3-4 neutropenia rose from 14 to 58% 
(P < .001). In the entire group, a higher risk in the same order of magnitude was noted, 
whereas no eff ects on diarrhea were seen (data not shown). 
Apart from hematological and gastrointestinal toxicity, also modest renal toxicity was 
encountered during treatment. In particular, creatinine clearance decreased from 103 
to 95 mL/min (P < .001), refl ecting an increase of serum creatinine from 75 to 85 μmol/L 
(P < .001). In a multiple regression analysis including age, baseline creatinine, gender, 
height, weight, BSA, and the exposure (area under the plasma concentration-time curve 
(AUC)) to irinotecan, SN-38, and SN-38G, the percentage increase of serum creatinine 
from baseline only related to the exposure to SN-38G (ρ = .37; P < .001).
Figure 2. Eff ects of renal function on irinotecan-induced neutropenia
The percentage of grade 3-4 neutropenia, graded according to the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events version 3.0, is plotted against the creatinine clearance calculated 
according to Cockcroft-Gault in all patients (A) and in the non-smoking patients (B) available for toxicity 
analysis. Group 1 represents a creatinine clearance > 130 mL/min, group 2 a creatinine clearance between 
98 and 130 mL/min, group 3 a creatinine clearance between 66 and 98 mL/min, and group 4 a creatinine 
clearance between 35 and 66 mL/min.
A B
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DISCUSSION
This study suggests that renal function is a predictor of the hematological toxicity profi le 
of irinotecan. Patients with a lower pretreatment renal function, as determined by the 
Cockcroft-Gault formula, had a higher risk of severe neutropenia. Given the low inci-
dence of neutropenia in smoking patients, this fi nding appears to be especially relevant 
to non-smoking patients. Compared to patients with a higher creatinine clearance (over 
98 and over 130 mL/min), patients with a low creatinine clearance (35-66 mL/min) had a 
2.5-times and 4.1-times higher risk of severe neutropenia, respectively. It has been sug-
gested that this eff ect should be attributed to decreased drug excretion,31,32 however, in 
the currently studied cohort of patients, exposure to irinotecan and SN-38 was not found 
to be signifi cantly related to renal function. These data complement existing knowledge 
on the toxicity profi le of irinotecan and may have important practical implications for 
its optimal use.
A limitation of this study is that only a small number of patients with a creatinine 
clearance < 60 mL/min could be included, since in clinical practice irinotecan is mostly 
administered to patients with adequate renal function, i.e., an estimated creatinine 
clearance over 60 mL/min. All clinical studies included in this analysis contained an 
exclusion criterion in this line.3,6,10,19-24 Because of this skewed distribution, an alterna-
tive categorization of renal function, based on its mean and SD, was chosen instead 
of conventionally used categorizations. Using the categorization according to the FDA, 
it was only possible to compare patients with a creatinine clearance over 80 mL/min 
to patients with a mildly impaired renal function (i.e., creatinine clearance between 
50 and 80 mL/min), which resulted in comparable fi ndings. Despite its limitations, the 
nonconventional categorization was chosen deliberately to investigate the eff ects of 
renal function on irinotecan pharmacokinetics and toxicity in its full nature and to be 
able to extrapolate fi ndings. Indeed, the risk of grade 3-4 neutropenia progressively 
increased with lower estimated creatinine clearances, strongly suggesting an eff ect of 
pretreatment renal function on irinotecan toxicity. 
Although no signifi cant relationship could be established between renal function and 
irinotecan clearance, a potential (partial) relationship cannot be completely ruled out. 
Especially not since patients with lower creatinine clearance (i.e., between 35 and 66 mL/
min) had a somewhat lower (13%) clearance of irinotecan than patients with a higher 
creatinine clearance (i.e., over 98 mL/min), which is in line with earlier fi ndings relating 
exposure to irinotecan to the severity of neutropenia.4,5,8 However, given its borderline 
signifi cance and the limited diff erence between both groups, this explanation cannot 
be the sole factor, if contributory at all. In addition, exposure to the active irinotecan 
metabolite SN-38, which is considered to predict the occurrence of neutropenia even 
stronger,4,5,8 was comparable between both groups. 
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In the context of mechanisms associated with renal elimination of camptothecins, 
it is important to emphasize that both irinotecan and its metabolites are known to be 
excreted by a variety of anion-transporting polypeptide binding cassette (ABC) drug 
transporters, such as ABCB1 (P-glycoprotein), ABCG2 (BCRP), and ABCC2 (cMOAT; MRP2). 
Given the affi  nity of irinotecan for multiple transporters, an eff ect of these transport-
ers on irinotecan clearance was hypothesized.32 In our study, however, no signifi cant 
relationships of renal function with the plasma pharmacokinetics of irinotecan, SN-38 
or SN-38G were demonstrated, which was in line with an earlier study.18 It should be 
pointed out that in this previous study, irinotecan was administered at a low dose of 225 
mg/m2 to only nine patients with a degree of renal impairment that was worse than that 
observed in the currently studied group with the lowest creatinine clearance. 
The lack of a statistically signifi cant relationship between renal function and plasma 
pharmacokinetics is potentially related, in part, to the possibility that the causative fac-
tor of impaired renal function is impaired tubular secretion, not fi ltration. Furthermore, 
the measures of systemic exposure were based on a composite chromatographic analy-
sis that combines the total of lactone (active) and carboxylate (inactive) forms of this 
anticancer drug,33 and urine data were not available to directly assess this possibility. 
Nonetheless, it is likely that the carboxylate form of camptothecins is more sensitive to 
the active secretion process that regulates the initial drug uptake from the circulation 
into the kidney.34 Likewise, CPT-11 and SN-38 have been shown to be mainly excreted 
into bile in the carboxylate form.35 Based on expression levels and localization, the 
organic anion transporters OAT1 and OAT3 are the most plausible candidates involved 
in this process, with the latter being presumably more important on the basis of recent 
information published for the related camptothecin, topotecan.36 
Impaired renal function has also been associated with increased circulating concen-
trations of renal toxins that inhibit organic anion-transporting polypeptide-mediated 
uptake of drugs into the liver. This is one of the proposed mechanisms for decreased 
CYP3A function (and thus potentially higher exposure to SN-38 in case of irinotecan 
therapy), as estimated by the erythromycin breath test, in patients with impaired renal 
function.37 However, since no eff ects on the plasma pharmacokinetics of irinotecan as 
function of renal function could be demonstrated, this is not likely to play a signifi cant 
role. 
Several UGT isoforms have been shown to catalyze the formation of acyl glucuro-
nides, including UGT1A3, UGT1A9, and particularly UGT2B7.38 Acyl glucuronides are 
potentially reactive intermediates, which undergo hydrolysis and intramolecular acyl 
migration, and also bind irreversibly to plasma proteins.39-42 To date, formation of acyl 
glucuronides in the metabolic pathway of irinotecan has not been shown. However, 
given the presence of a lot of unidentifi ed (minor) metabolites in urine, bile, and plasma, 
the formation of acyl glucuronides cannot be excluded on forehand. Although highly 
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speculative, a role for such toxic compounds might be considered in line with the rela-
tionships found here between baseline renal impairment and decreased renal function 
during treatment versus the exposure to the water soluble glucuronide conjugate of 
SN-38. 
Typically, for drugs substantially eliminated by the kidneys, dose adjustments in pa-
tients with renal dysfunction are required either by dose reduction or by prolongation 
of the administration interval. Such recommendations should be based on prospective 
pharmacokinetic study data and the observed effi  cacy and toxicity of the drug. However 
for irinotecan, strong data on toxicity in this specifi c population are lacking.18 Most re-
ports are case reports describing renally impaired patients being treated with irinotecan 
and/or studying renally impaired patients being treated with lower irinotecan doses, 
making it diffi  cult to assess whether full dosing of irinotecan in renal impaired patients 
is feasible. Since such data are currently scarce for irinotecan, its package label states to 
be cautious with its use in renally impaired patients without giving more precise dosing 
guidelines. 
Because many factors aff ect irinotecan toxicity, tailored dosing of irinotecan remains 
diffi  cult in the post-BSA era. Many of the possible determinants of irinotecan and SN-38 
exposure have been investigated and numerous attempts have been made to predict 
the individual patient’s clearance before irinotecan administration using this knowledge 
to calculate a dose ultimately resulting in a controlled, predictable, and safe exposure. 
Most attention has been focused on hepatic factors; in particular, the homozygous 
presence of the UGT1A1*28 allele has been identifi ed as a risk factor for the occurrence 
of irinotecan-induced toxicity.4,8 The package label of irinotecan has been changed 
accordingly, incorporating a statement regarding dose adjustment for homozygous 
UGT1A1*28 carriers. However, nonhepatic factors, such as renal function and lifestyle, 
should not be disregarded, particularly, since the group of homozygous UGT1A1*28 car-
riers is relatively small,8 whereas more patients are prone to irinotecan-induced toxicity 
because of lifestyle behavior (e.g., use of alcohol, herbal tea, and complementary and 
alternative medicine). Other subgroups of patients may be prone to toxicity because 
of the presence of other (relatively rare) genetic risk factors. Additionally, although 
strong relationships between toxicity and systemic exposure to SN-38 have been 
demonstrated, it cannot be excluded that neutropenia after irinotecan application is 
mediated through other pathways as well. For example, as stated in its package label, 
older age (> 65 years), prior radiotherapy, and a World Health Organization performance 
score over 2 have been identifi ed as risk factors for the occurrence of irinotecan-induced 
toxicity. Additionally, in patients receiving low dose, protracted irinotecan, UGT1A1*28 
status correlated with SN-38 pharmacokinetics, but not with toxicity.43 
Because delayed-onset diarrhea and neutropenia contribute to the risk of developing 
febrile neutropenia, many attempts have been undertaken to reduce their incidence 
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and severity. For example, withholding UGT1A1*28 homozygous patients full-dosed 
irinotecan, the overall incidence of grade 4 neutropenia will decrease from 10 to 6%. De-
pending on the exact criteria used for defi ning febrile neutropenia and the population 
under study (e.g., pretreatment, tumor type, age, performance score, etc.) the incidence 
of febrile neutropenia of 1-15% in the three weekly schedule of 350 mg/m2,44-46 does not 
justify a primary prophylactic role of granulocyte colony-stimulating factors.47 However, 
to avoid febrile neutropenia, infections, and (a priori) dose reductions in renally impaired 
patients, it may be worth investigating the clinical and economic benefi ts of prophylactic 
treatment with granulocyte colony-stimulating factors, like (pegylated) fi lgrastim (Ne-
upogen/Neulasta; Amgen, Thousand Oaks, CA) in these patients. Particularly, given the 
fact that renal function does not appear to signifi cantly aff ect the exposure to SN-38 and 
the occurrence and severity of delayed-onset diarrhea, which has recently been related 
to the detoxifi cation of SN-38 in the intestinal mucosa,29,48 a cautious use of irinotecan 
in renally impaired patients, as suggested in its package label, may result in suboptimal 
exposure to SN-38 and a subsequent lower chance on therapeutic effi  cacy,49-51 if a priori 
dose reductions are applied. 
In conclusion, this study suggests that lower creatinine clearance is associated with a 
fourfold increased risk of irinotecan-induced neutropenia (14% versus 58%), especially 
in non-smoking patients. Although the exact mechanism of this interaction remains to 
be established, the current data suggest that further investigation is warranted to deter-
mine whether renal function should be considered as an important factor in irinotecan 
dose-optimization and a valuable addition to the toolbox to individualize irinotecan 
therapy.
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ABSTRACT
Background 
Omeprazole is one of the most prescribed medications worldwide and within the class 
of proton pump inhibitors, it is most frequently associated with drug interactions. In 
vitro studies have shown that omeprazole can alter the function of metabolic enzymes 
and transporters that are involved in the metabolism of irinotecan, such as uridine 
diphosphate glucuronosyltransferase subfamily 1A1 (UGT1A1), cytochrome P-450 en-
zymes subfamily 3A (CYP3A) and the ATP-binding cassette drug transporter G2 (ABCG2). 
In this open-label cross-over study we investigated the eff ects of omeprazole on the 
pharmacokinetics and toxicities of irinotecan.
Methods 
Fourteen patients were treated with single agent irinotecan (600 mg i.v., 90 minutes) 
followed 3 weeks later by a second cycle with concurrent use of omeprazole 40 mg 
once daily, which was started two weeks prior to the second cycle. Plasma samples 
were obtained up to 55 hours after infusion and analysed for irinotecan and its 
metabolites 7-ethyl-10-hydroxycampothecin (SN-38), SN-38-glucuronide (SN-38G), 
7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin (NPC) and 7-ethyl-
10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC) by 
high-performance liquid chromatography (HPLC). Non-compartmental modelling was 
performed. Toxicities were monitored during both cycles. Paired statistical tests were 
performed with SPSS.
Results 
The exposure to irinotecan and its metabolites was not signifi cantly diff erent between 
both cycles. Neither were there signifi cant diff erences in the absolute nadir and per-
centage decrease of WBC and ANC, nor on the incidence and severity of neutropenia, 
febrile neutropenia, diarrhea, nausea and vomiting when irinotecan was combined with 
omeprazole.
Conclusion 
Omeprazole 40 mg did not alter the pharmacokinetics and toxicities of irinotecan. This 
widely used drug can therefore be safely administered during a three-weekly single 
agent irinotecan schedule.
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INTRODUCTION
Drug-drug interactions can cause serious adverse eff ects, especially in oncology, as a 
result of the narrow therapeutic window of chemotherapeutic agents. Small changes in 
the pharmacokinetics or pharmacodynamics of chemotherapy caused by another drug 
can result in signifi cant changes in its toxicity or effi  cacy. Because cancer patients often 
experience disease-related and age-related organ failure, they frequently use several 
other drugs, which put them at risk for drug-drug interactions.1 
Proton pump inhibitors (PPIs) act as potent blockers of the gastric acid pump without 
major side eff ects.2 They belong to one of the most frequently prescribed medications 
in the United States.3 
Omeprazole was the fi rst registered proton pump inhibitor and is one of the most 
prescribed drugs worldwide.4,5 Although widely used, being approved as over-the-
counter product in several countries, and mostly designated as harmless, omeprazole 
is actually known to be involved in several drug-drug interactions,6 which could poten-
tially be dangerous when combined with drugs with a narrow therapeutic window, such 
as chemotherapeutic agents. 
Several drug-drug interaction studies with omeprazole have been performed, mainly 
focusing on interactions on the level of hepatic cytochrome P450 (CYP) enzymes and 
alteration of the absorption of (oral) drugs via changes in gastric pH. Clinically, the most 
important drug-drug interaction of omeprazole is a 27-54% reduction in clearance of 
diazepam due to competitive inhibition of CYP2C19.7,8 Next to this eff ect there are in 
vivo and in vitro results pointing to induction of UDP-glucuronosyltransferases,9-11 in-
duction12,13 and inhibition of cytochrome P-450 enzymes subfamily 3A (CYP3A),14,15 and 
inhibition of the ATP-binding cassette drug transporter B1 (ABCB1)14,15 and ATP-binding 
cassette drug transporter G2 (ABCG2).16,17 These metabolising enzymes and drug 
transporters play an important role in the disposition of the topoisomerase-I inhibitor 
irinotecan (Campto®, Pfi zer), which is registered for the treatment of metastatic and/or 
inoperable colorectal cancer (Figure 1).
In vitro research of the combination of irinotecan and omeprazole showed an 85% 
reduction of 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin (NPC) 
formation, one of the metabolites of irinotecan, which could potentially lead to in-
creased levels of the active metabolite 7-ethyl-10-hydroxycampothecin (SN-38) and 
consequently more severe toxicity.18 We performed comparable in vitro experiments and 
the results led us to initiate a clinical study to investigate the eff ect of omeprazole on the 
pharmacokinetics of irinotecan and toxicities in cancer patients.
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MATERIALS AND METHODS
In vitro studies
In vitro experiments were performed to study the eff ect of omeprazole on the me-
tabolism of irinotecan. Pooled human liver microsomes (Becton Dickinson Gentest) 
were incubated for 30 minutes with irinotecan (10 μM) in the presence or absence of 
omeprazole (25 μM) or fl uconazole (25 μM; CYP3A inhibitor) based on an earlier de-
ABCB1
CYP3A4/5
CES1/2
ABCC2IrinotecanAPC
CES1/2 ABCB1 ABCG2
SN 38NPC
UGT1A1/7/9β-glucuronidase
ABCC2-
SN-38G ABCG2
ABCC2
Figure 1. Metabolism of irinotecan
The prodrug irinotecan is metabolized into its active metabolite SN-38 by carboxylesterases type 1 and 
2. The affi  nity for this reaction is low, since only a fraction of irinotecan is directly converted into SN-38. 
Competing with the formation of SN-38 is the oxidation of irinotecan into the inactive metabolites APC 
and NPC by CYP3A4 and CYP3A5, which both (partially) can be converted further into SN-38. To facilitate 
excretion, SN-38 is glucuronidated into its inactive metabolite SN-38-glucuronide (SN-38G) by several 
UGT1A isoforms; UGT1A1 being the most important. In the intestines, SN-38G can be deglucuronidated 
into SN-38 by β-glucuronidase-producing bacteria. Several drug transporters are involved in the 
elimination of irinotecan and its metabolites. 
Abbreviations: ABCB1, ATP-binding cassette drug-transporter B1, also known as P-glycoprotein; 
ABCC2, ATP-binding cassette drug-transporter C2, also known as canalicular multispecifi c organic 
anion transporter (C-MOAT); ABCG2, ATP-binding cassette drug transporter G2, also known as Breast 
Cancer Resistance Protein (BCRP); APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-
carbonyloxycamptothecin, inactive metabolite of irinotecan; CES, carboxylesterase; CYP3A; cytochrome 
P-450 enzymes subfamily 3A; NPC, 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, 
inactive metabolite of irinotecan; SN-38, 7-ethyl-10-hydroxycampothecin, active metabolite of 
irinotecan; SN-38G, SN-38-glucuronide, inactive metabolite of SN-38; UGT1A, uridine diphosphate 
glucuronosyltransferase subfamily 1A.
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scribed method.19 The experiments were performed on four separate occasions. In each 
experiment, microsomes (1 mg protein/mL) were incubated in triplicate. In another ex-
periment, microsomes (0.8 mg/mL) were co-incubated for 30 minutes with SN-38 (5 μM) 
and omeprazole (25 μM) and ketoconazol (25 μM; uridine diphosphate glucuronosyl-
transferase subfamily 1A (UGT1A) inhibitor) based on methods described.20 Experiments 
were terminated by the addition of perchloric acid/methanol. Irinotecan and metabolite 
concentrations were analyzed based on validated assays.21,22 
HCT116 (colorectal carcinoma) and Caco2 (colorectal adenocarcinoma) cells were 
cultured in Hepes-buff ered RPMI 1640 medium supplemented with Glutamax™, 10% fetal 
bovine serum (Gibco), 100 U/mL penicillin and 100 μg/mL streptomycin at 37C in a hu-
midifi ed atmosphere containing 5% CO2. Cells were cultured for 24 hours in the presence 
of 25 μM omeprazole or 0.1% (v/v) DMSO as solute control. After 24 hours, total RNA was 
extracted using RNA-Bee (Tel-TEST Temco, Inc.). Relative UGT1A1 expression levels were 
measured by real time RT-PCR using Taqman Universal Master mix and Assay-On-Demand 
products from Applied Biosystems (UGT1A1 assay ID: Hs02511055-s1). The human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH assay ID: 4310884E; VIC/TAMRA) 
was used for normalization. Reactions were run on an ABI PRISM 7900 sequence detector 
system (Applied Biosystems) using the following cycling conditions: 50C for 2 minutes, 
95C for 10 minutes followed by 40 cycles of 95C for 15 seconds, and 60C for 1 minute.
Patients
Nineteen patients were included in this open-label cross-over interaction study. Inclu-
sion criteria were: (1) histological or cytological confi rmed diagnosis of any form of 
(irresectable and/or metastatic) cancer, which was thought to be sensitive to irinotecan 
treatment; (2) age ≥ 18 years; (3) WHO performance score ≤ 1; and (4) adequate hemato-
logical, renal and hepatic function. Starting two weeks before irinotecan administration, 
patients were not allowed to use grapefruit, star fruit, dietary supplements, St. John’s 
wort, herbal tea and herbals or any other known inhibitor and/or inducer of CYP3A and 
ABCB1. In addition, the use of proton pump inhibitors was prohibited. Specifi c exclu-
sion criteria were: (1) any form of anticancer treatment within four weeks of start of 
irinotecan administration; (2) unresolved bowel obstruction or chronic colic disease; and 
(3) any form of illness that would prohibit the process of understanding and giving of 
informed consent. All patients gave written informed consent and the local institutional 
review board approved the clinical protocol, which was written in accordance with the 
declaration of Helsinki.
Treatment
All patients received their fi rst cycle of irinotecan (Campto®, Pfi zer) without and their 
second cycle with concomitant omeprazole (Losec®MUPS®, AstraZeneca). Fourteen 
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days before the start of the second cycle, patients started with omeprazole 40 mg once 
daily until the third day after the second administration. Irinotecan was administered 
intravenously over 90 minutes at a fl at-fi xed dose of 600 mg during both cycles.23 All 
patients received a standard antiemetic regimen of intravenous granisetron (1 mg) and 
dexamethason (10 mg) 30 minutes before the administration of irinotecan and atropine 
(0.25 mg, subcutaneously) prior to irinotecan infusion, to prevent an acute cholinergic 
syndrome. For the treatment of irinotecan-induced diarrhea, patients received treat-
ment with loperamide and, when necessary, antibiotics. A dose reduction of 25% was 
performed at the discretion of the physician, when necessary. Patients were asked to 
record side eff ects, the intake of any other drugs during both treatment cycles and the 
time of intake of omeprazole in a specifi c diary.
Pharmacokinetic analyses of irinotecan
Pharmacokinetic analyses of irinotecan and its main metabolites SN-38, SN-38G, APC 
and NPC were performed during both treatment cycles. Blood samples (5 mL; lithium-
heparin) were collected prior to infusion, 30 minutes after the start of infusion, at the 
end of infusion, as well as 10, 20 and 30 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 22.5, 30, 46.5 and 
53.5 hours post-infusion. Samples were centrifuged for 10 minutes at 2,860 g (4C) and 
plasma was stored at -80C until analysis by validated reversed-phase high-performance 
liquid chromatography assays with fl uorescence detection, as described elsewhere.21,22,24 
Pharmacokinetic parameters of irinotecan and its metabolites were calculated using 
weighted non-compartmental analyses with WinNonLin 5.2 (Pharsight Corp., Mountain 
View, CA).
Toxicities
During both cycles, patients were seen weekly at the outpatient clinic for physical ex-
amination, toxicity screening and laboratory tests. Leukopenia, neutropenia, diarrhea, 
nausea and vomiting were graded using the Common Terminology Criteria for Adverse 
Events (CTC) version 3.0,25 and were also classifi ed into severe (grade 3-4) and not severe 
(grade 0-2). In addition, leukopenia and neutropenia were evaluated as absolute nadir 
and as percentage decrease at nadir from baseline which was calculated as: percentage 
decrease = [baseline value – nadir value]/baseline value × 100%. Toxicity analyses were 
only performed in the group of patients who received two full dose cycles of irinotecan 
(600 mg; N = 12).
Genotyping
In all patients, UGT1A1-genotype analyses were performed for the UGT1A1*28 
((TA)6→(TA)7) and UGT1A1*93 (-3156G>A) polymorphisms as described.26 In addition, 
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patients were screened for being an ultra-rapid metabolizer of CYP2C19 (CYP2C19*17),27 
which may result in a sub-therapeutic exposure to omeprazole.27,28
Statistics
The primary objective of this study was to investigate the infl uence of omeprazole on 
the plasma pharmacokinetics of irinotecan and its metabolites in cancer patients. To 
detect a 25% diff erence in SN-38 AUC between the cycles with and without concomitant 
omeprazole with a two-sided signifi cance level of 5% and a power (1-β) of 90%, a sample 
size of at least 14 patients was required. For the sample size calculation, data were used 
from patients who received two subsequent cycles of irinotecan at a fl at-fi xed dose of 
600 mg.26 Dose-reduced patients were excluded from this analysis. The secondary objec-
tive was to compare side eff ects, especially leukopenia and neutropenia, and late-onset 
diarrhea, in the presence and absence of omeprazole. 
Data are presented as mean values with 95% confi dence intervals, unless stated 
otherwise. To compare pharmacological parameters and nadir and percentage decrease 
of neutrophils and leukocytes between the cycle with and without omeprazole, paired 
t-tests were used. For the comparison of the CTC-graded toxicities between both cycles, 
Mc Nemar’s test was used. Statistical tests were calculated two-sided and P-values of 
less than .05 were regarded as statistically signifi cant. All statistical calculations were 
performed with SPSS version 15.0 (SPSS Inc., Chicago, IL).
RESULTS
In vitro experiments
As shown in Figure 2, co-incubation of human liver microsomes with irinotecan and 
omeprazole resulted in an 80% inhibition on NPC formation and a 75% inhibition on 
APC formation, which was comparable with results with the CYP3A inhibitor fl uconazole 
(78% and 74% inhibition, respectively). Although in vitro no eff ect of omeprazole was 
seen on the formation of SN-38, the inhibition of both NPC and APC formation could 
potentially lead to higher SN-38 levels in vivo. 
Also shown in Figure 2, co-incubation of human liver microsomes with SN-38 and 
omeprazole did not result in reduced formation of SN-38G, whereas the formation of 
SN-38G was reduced with 57% when SN-38 was co-incubated with the UGT1A1 inhibitor 
ketoconazole. 
A 24-hour exposure of the colorectal carcinoma cell Lines HCT116 and Caco2 to 25 μM 
omeprazole resulted in a two-fold up-regulation of UGT1A1 mRNA levels as determined 
by quantitative RT-PCR.
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Patients
Nineteen patients were included in the clinical study. Two patients did not start treat-
ment after registration; one due to the diagnosis of a second malignancy, the other 
due to progressive liver failure. One patient did not receive a second administration of 
irinotecan because of severe toxicity during the fi rst cycle (grade 4 diarrhea and hema-
tological toxicity). One patient was not evaluable for pharmacokinetics due to ascites 
with possible third space pharmacokinetics. Another patient was not evaluable due to 
problems with pharmacokinetic sampling. Of the 14 evaluable patients for pharmacoki-
netics, two patients were not evaluable for toxicity analysis due to 25% dose reduction 
during their second cycle because of severe toxicity (grade 4 hematological toxicity plus 
grade 3 gastrointestinal toxicities and grade 3 hepatological toxicity, respectively). The 
pharmacokinetics of these dose-reduced cycles were extrapolated to full dose pharma-
cokinetics, since the pharmacokinetics of irinotecan and its metabolites are linear in this 
dose range.29 Patient demographics are stated in Table 1.
Figure 2. Omeprazole aff ects the metabolism of irinotecan in vitro
Eff ect of omeprazole (grey bars) and CYP3A inhibitor fl uconazole (white bars) on the formation of NPC, 
APC and SN-38 during incubation of human liver microsomes with irinotecan and eff ect of omeprazole 
(grey bars) and UGT1A1 inhibitor ketoconazole (white bars) on the formation of SN-38G during incubation 
with SN-38. The black bars represent the formation of metabolites in the absence of a potential inhibitor. 
Depicted are the mean values of the formed metabolite + SD. 
Abbreviations: APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, 
inactive metabolite of irinotecan; CYP3A, cytochrome P-450 enzymes subfamily 3A; NPC, 7-ethyl-10-[4-(1-
piperidino)-1-amino]-carbonyloxycamptothecin, inactive metabolite of irinotecan; SD, standard deviation; 
SN-38, 7-ethyl-10-hydroxycampothecin, active metabolite of irinotecan; SN-38G, SN-38-glucuronide, 
inactive metabolite of SN-38; UGT1A1, uridine diphosphate glucuronosyltransferase subfamily 1A1.
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Irinotecan pharmacokinetics
As shown in Table 2, there was no signifi cant diff erence in the area under the curve 
(AUC) and maximum concentration (Cmax) of irinotecan (P > .24), SN-38 (P > .63), SN-38G
(P > .07), APC (P > .07) and NPC (P > .13) between the cycles with and without omepra-
zole. Similar results were obtained when the two ultra-rapid metabolizers of CYP2C19 
(CYP2C19*17/*17) were left out of analysis (P > .06). Figure 3 shows the time versus plas-
Table 1. P atient characteristics a
Characteristics N % Median Range
Age (years) 65 26-74
BSA (m2) 1.87 1.59-2.38
Sex
 Male 9 64%
 Female 5 36%
Tumor type
 Colorectal 4 29%
 Pancreatic 4 29%
 (A)CUP 2 14%
 Miscellaneousb 4 29%
Smoking status
 Smoker 1 7%
 Non-smoker 13 93%
UGT1A1*28 genotype
 TA6/TA6 (wildtype) 7 50%
 TA6/TA7 7 50%
 TA7/TA7 0 0%
UGT1A1*93 genotype
 GG (wildtype) 9 64%
 GA 5 36%
 AA 0 0%
CYP2C19*17 genotype
 CC (wildtype) 5 36%
 CT 7 50%
 TT 2 14%
Ab breviations: (A)CUP, (adeno)carcinoma of unknown primary; BSA, body surface area; UGT1A1*28, 
polymorphism for an additional (seventh) repeat in the TATA box of the promoter region of UGT1A1 
leading to reduced UGT1A1 formation; UGT1A1*93, polymorphism in the UGT1A1 gene, also known as 
-3156G>A, resulting in less functional UGT1A1; CYP2C19*17, polymorphism in CYP2C19 gene (-806C>T 
and -3402C>T), resulting in more functional CYP2C19 (ultra rapid metabolizer).
a  N = 14, patients evaluable for two treatment cycles.
b Including primitive neuro-ectodermal tumour (1), cho langiocarcinoma (1), jejunal carcinoma (1) and 
breast cancer (1).
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ma concentration curves of irinotecan and its metabolites as well as the intra-individual 
AUCs with and without concomitant omeprazole.
Toxicities
No statistical diff erences were seen in the absolute nadir and percentage decrease of leu-
kocytes and neutrophils after irinotecan treatment with or without omeprazole (P > .34; 
Table 3). In addition, no diff erences were seen in the incidence of severe leukopenia and 
neutropenia (P = 1.0). Overall, the incidence of severe (grade 3-4) gastrointestinal toxici-
ties was low in our study. Only 2 patients suff ered from grade 3 or 4 diarrhea, nausea 
and vomiting.
Table 2. P harmacokinetics of irinotecan and its metabolites without (–) and with (+) concomitant use of 
omeprazole
Parametera Omeprazole (–) Omeprazole (+) Ratiob P 
Irinotecan
 AUC 0–55h (ng×h/mL) 24,498 (16,186-32,811) 23,472 (16,195-30,748) 0.97 (0.92-1.02) .24
 Cmax (ng/mL) 3,700 (2,998-4,401) 3,585 (2,814-4,355) 0.97 (0.90-1.04) .34
SN-38
 AUC0–55h (ng×h/mL) 439 (346-533) 453 (354-551) 1.05 (0.92-1.19) .63
 Cmax (ng/mL) 41.9 (29.9-53.9) 43.0 (31.7-54.3) 1.09 (0.87-1.31) .81
SN-38G
 AUC0–55h (ng×h/mL) 2,913 (1,874-3,953) 3,167 (1,963-4,371) 1.08 (0.96-1.19) .15
 Cmax (ng/mL) 209 (155-264) 228 (165-291) 1.09 (1.00-1.19) .07
APC
 AUC0–55h (ng×h/mL)
c 7,471 (4,944-9,998) 6,438 (5,016-7,859) 0.94 (0.80-1.07) .15
 Cmax (ng/mL)
c 587 (393-781) 476 (378-575) 0.90 (0.77-1.04) .07
NPC
 AUC0–55h (ng×h/mL) 189 (114-265) 154 (119-189) 0.92 (0.75-1.09) .25
 Cmax (ng/mL) 19.9 (12.5-27.3) 15.0 (12.5-17.5) 0.89 (0.72-1.05) .13
Ab breviations: APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, 
inactive metabolite of irinotecan; AUC0–55h, area under the concentration-time curve from 
timepoint 0 to 55 hours; Cmax, maximum concentration; NPC, 7-ethyl-10-[4-(1-piperidino)-1-amino]-
carbonyloxycamptothecin, inactive metabolite of irinotecan; SN-38, 7-ethyl-10-hydroxycampothecin, 
active metabolite of irinotecan; SN-38G, SN-38-glucuronide, inactive metabolite of SN-38.
a Da ta presented as mean with 95% confi dence interval in parentheses.
b Ratio of mean pharmacokinetic parameters of irinotecan with and withou t omeprazole [ratio = with 
omeprazole/without omeprazole].
c N = 13, data on pharmacokinetics of APC missing in one patient.
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Figure 3. Pharmacokinetics of irinotecan with and without concomitant omeprazole
A-E. Mean (± 95% confi dence interval) plasma concentration-time curves of irinotecan (A), SN-38 (B), SN-
38G (C), APC (D) and NPC (E) in 14 cancer patients after intravenous infusion of 600 mg irinotecan, with 
(closed circles) and without (open circles) concomitant use of omeprazole 40 mg once daily. 
F-J. Intraindividual (open circles) and mean (closed circle) area under the curve (AUC) of irinotecan (F), 
SN-38 (G), SN-38G (H), APC (I, N = 13) and NPC (J) of 14 cancer patients treated with irinotecan 600 mg 
intravenously with and without concomitant use of omeprazole 40 mg once daily.
Abbreviations: APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, 
inactive metabolite of irinotecan; NPC, 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, 
inactive metabolite of irinotecan; SN-38, 7-ethyl-10-hydroxycampothecin, active metabolite of irinotecan; 
SN-38G, SN-38-glucuronide, inactive metabolite of SN-38.
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DISCUSSION
Here we investigated the possible drug-drug interaction between the proton pump in-
hibitor omeprazole and irinotecan. No eff ect of co-administration of omeprazole on the 
pharmacokinetics and toxicities of irinotecan and its metabolites was seen. Two patients 
in our study were characterised as CYP2C19 ultra-rapid metabolizers, which could have 
infl uenced our results as they could have had suboptimal levels of omeprazole. However, 
when these patients were excluded from analysis, there still was no signifi cant infl uence 
of omeprazole on the pharmacokinetics and toxicities of irinotecan and its metabolites. 
Since irinotecan has a complex disposition profi le involving several drug-metaboliz-
ing enzymes and drug transporters, drug-drug interactions can occur at several levels. 
In recent years, several herbs and drugs were combined with irinotecan to investigate 
the possibility of a drug interaction, potentially explaining the occurrence of treatment 
failure or severe side eff ects, such as neutropenia and late-onset diarrhea. For example, 
a reduced exposure to irinotecan and its potent metabolite SN-38 was seen when irino-
tecan was combined with the CYP3A inducer phenytoin.30,31 Concomitant smoking also 
resulted in reduced plasma concentrations of irinotecan and SN-38.32 Reduced levels 
of SN-38 were seen when irinotecan was combined with valproic acid,33 and with St. 
John’s wort.34 Higher levels of SN-38 were seen in combination with lopinavir/ritonavir 
and the combined CYP3A and UGT1A inhibitor ketoconazole,20,35,36 and when irinotecan 
was combined with tacrolimus.37 However, no eff ect was seen when irinotecan was 
combined with medicinal cannabis.38 
We detected a modest two-fold increase in UGT1A1 mRNA levels when colorectal 
carcinoma cell lines were cultured with omeprazole for 24 hours. Similarly Donato et 
Table 3. T oxicities of irinotecan without (–) and with (+) concomitant use of omeprazole of patients who 
received two full-dose treatments (N = 12)a
Parameter Omeprazole (–) Omep razole (+) P
Leukocytes
 Nadir (×109) 2.79 (2.00-3.59) 3.01 (2.07-3.95) .46
 Decrease (%)b 46.8 (31.3-62.4) 40.3 (17.6-63.0) .34
 Severe leukopenia (grade 3-4)c 5 (42%) 4 (33%) 1.00d
Neutrophils
 Nadir (×109) 1.47 (0.86-2.08) 1.43 (0.88-1.98) .87
 Decrease (%)b 57.4 (41.8-73.1) 49.6 (25.3-74.0) .35
 Severe neutropenia (grade 3-4)c 4 (33%) 5 (42%) 1.00d
a  Two patients were excluded from this analysis because of dose reduction during the second cycle due to 
severe toxicities during the fi rst cycle.
b Percentage decrease compared with baseline = [baseline value – nadir value]/baseline value × 100%.
c Number of patients with percentage in parenthe ses.
d Mc Nemar test.
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al. reported a six-fold induction of UGT1A1 activity in HepG2 cells when they were 
cultured in the presence of 50 μM omeprazole for 72 hours.9 This can be explained by 
the agonistic eff ect of omeprazole on the Ah-receptor,39 which is known to be involved 
in transcription of the UGT1A1 gene.40 However, in vivo omeprazole had no signifi cant 
inducing eff ect on the glucuronidation of SN-38, possibly because in vivo lower concen-
trations of the drug are present. 
Our results complement outcomes of other drug-drug interaction studies with 
omeprazole and anticancer drugs. For example, no eff ect of omeprazole was seen on the 
pharmacokinetics of the CYP3A substrates imatinib and bortezomib.41,42 However, the 
exposure to dasatinib was reduced in combination with omeprazole.43 The mechanism 
for this eff ect could be CYP3A4 induction or reduced gastric acid secretion which infl u-
ences the absorption of dasatinib. As irinotecan is administered intravenously, the latter 
cannot play a role in a possible interaction. And, in contrast with dasatinib, where only 
CYP3A4 is thought to play an important role in its metabolism,44 irinotecan has multiple 
enzymes that are involved in its disposition. 
A limitation of our study might be the fi xed-sequence design instead of a randomised 
design. We chose this design to avoid a possible infl uence of the diff erent sequences on 
the pharmacokinetics of irinotecan and to avoid treatment delay due to the two-weeks 
induction period for omeprazole. Although the sample size was large enough to detect 
a possible diff erence in pharmacokinetics according to the power analysis, this was a 
small study and the study was not powered to detect diff erences in toxicity outcome. 
To conclude, our results indicate that omeprazole 40 mg once daily can be safely 
combined with a single agent irinotecan schedule, administered once every three weeks. 
Since other proton pump inhibitors have a diff erent potential for drug-drug interac-
tions,45 eff ects of other proton pump inhibitors on the pharmacokinetics and toxicities 
of irinotecan should be further investigated, before they might be safely combined with 
irinotecan.
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ABSTRACT
Purpose 
To study the possible pharmacokinetic and pharmacodynamic interactions between 
irinotecan and methimazole.
Methods 
A patient treated for colorectal cancer with single agent irinotecan received methima-
zole co-medication for Graves’ disease. Irinotecan pharmacokinetics and side eff ects 
were followed during a total of four courses (two courses with and two courses without 
methimazole).
Results 
Plasma concentrations of the active irinotecan metabolite SN-38 and its inactive metab-
olite SN-38-glucuronide (SN-38G) were both higher (a mean increase of 14% and 67%, 
respectively) with methimazole co-medication, compared to irinotecan monotherapy. 
As a result, the mean SN-38 glucuronidation rate increased with 47% during concur-
rent treatment. Other possible confounding factors did not change over time. Specifi c 
adverse events due to methimazole co-treatment were not seen.
Conclusions 
Additional in vitro experiments suggest that these results can be explained by induction 
of UGT1A1 by methimazole, leading to higher SN-38G concentrations. The prescribed 
combination of these drugs may lead to highly toxic intestinal SN-38 levels. We therefore 
advise physicians to be very careful in combining methimazole with regular irinotecan 
doses, especially in patients who are prone to irinotecan toxicity.
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INTRODUCTION
Irinotecan is extensively used in the treatment of advanced colorectal cancer.1 It is a 
prodrug of the active compound SN-38 and is metabolized by cytochrome P450 3A 
(CYP3A) into inactive metabolites (Figure 1A). In the liver, uridine diphosphate gluc-
uronosyltransferase 1A (UGT1A) is capable of inactivating SN-38 to its glucuronide form 
SN-38G, which facilitates excretion from the circulation.2 In the intestines, SN-38G can be 
transformed back into SN-38 by bacterial β-glucuronidase. The metabolism of irinotecan 
is complicated by several drug-transporting proteins involved in the elimination of the 
drug (i.e. ATP-binding cassette transporters).3 Besides genetic alterations in the UGT1A 
gene, also environmental factors are known to infl uence its metabolism.3-5 For instance, 
cigarette smoking may induce its metabolism, thereby decreasing the systemic expo-
sure to SN-38.6
Here we report on a patient who used methimazole, while being treated with iri-
notecan chemotherapy. We hypothesized that methimazole could seriously infl uence 
irinotecan metabolism, as preclinical data suggest that methimazole inhibits CYP3A,7 
and induces certain UGT1A subtypes,8 both being crucial enzyme systems involved 
in the elimination of irinotecan and its metabolites. By performing additional in vitro 
experiments, we tested our hypothesis.
MATERIALS AND METHODS
Our patient was a cigarette smoking 53-year old male, with locally advanced colorectal 
cancer. Six months prior to the start of irinotecan treatment, he was treated for hyper-
thyroidism due to Graves’ disease using a combination of methimazole and levothyrox-
ine. Other daily medicines were acetaminophen, fentanyl, pantoprazole, carbasalate 
calcium, metoclopramide, and dexamethasone. During two three-weekly courses of 
irinotecan, the patient took a daily dose of 30 mg methimazole. Two weeks after the sec-
ond chemotherapy course, methimazole was stopped and the patient was treated with 
radioiodine (I-131) as a defi nitive treatment for Graves’ hyperthyroidism. Without delay, 
the following courses of irinotecan were administered. After written informed consent, 
plasma pharmacokinetics of irinotecan and its metabolites were collected during a total 
of four courses. Patient-related factors (i.e., co-medication, smoking status), laboratory 
values and toxicities were closely monitored, UGT1A1*28 genotype was determined, 
and active hormone 3,5,3’-triiodothyronine (T3), and thyroid stimulating hormone (TSH, 
thyrotropin) levels were determined to exclude possible confounding eff ects of varying 
thyroid status.
During and after the 90-minute intravenous infusions of irinotecan (350 mg/m2), 
blood was drawn at specifi c time points.6 Plasma concentrations of irinotecan, NPC, APC, 
SN-38, and SN-38G were determined using validated chromatography methods.9,10 In-
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Figure 1. Pharmacokinetics of irinotecan and metabolites
A. Irinotecan is converted into its 1,000 times more active metabolite SN-38 by carboxylesterases (CES), 
which are predominately found in the liver. The affi  nity for this reaction is low, since only a fraction 
of irinotecan is directly converted into SN-38. Competing with the formation of SN-38 is the CYP3A-
mediated inactivation of irinotecan into the metabolites APC and NPC. In turn, carboxylesterases also 
have the ability to convert both of these compounds into SN-38. SN-38 is glucuronidated by UGT1A into 
its inactive metabolite SN-38G. In the intestines, β-glucuronidase-producing bacteria can reverse this 
latter reaction, and thus reactivate SN-38, which causes the dose-limiting toxicity diarrhea. 
B-F. Area under the plasma concentration-time curves for irinotecan (B), SN-38 (C), SN-38G (D), APC (E), 
and NPC (F) during all four chemotherapy courses. The open and closed symbols describe the two courses 
with methimazole and the two courses without methimazole co-treatment, respectively.
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dividual plasma pharmacokinetics were estimated using non-compartmental analyses 
(WinNonLin 5.0, Pharsight, CA). At weekly outpatient visits, toxicities were scored. 
Methods of in vitro experiments
In vitro experiments were performed to study the eff ects of methimazole on the me-
tabolism of irinotecan and SN-38. Pooled human liver microsomes were incubated for 
30 minutes with irinotecan (10 μM) in the presence or absence of methimazole (37.5 μM) 
or fl uconazole (25 μM; CYP3A inhibitor) based on the method described by Slatter et al.11 
The experiment was performed on four separate occasions. In each experiment, 
microsomal proteins (1 mg/mL) were incubated in triplicate. In addition, pooled human 
liver microsomes were incubated for 30 minutes with SN-38 (5 μM) in the presence or 
absence of methimazole (37.5 μM) or ketoconazole (25 μM; UGT1A inhibitor) based 
on the method described by Yong et al.12 This experiment was performed on separate 
occasions, during which microsomal proteins (0.8 mg/mL) were incubated in triplicate. 
Experiments were terminated by the addition of a perchloric acid/methanol solution. 
Irinotecan and metabolite concentrations from these experiments were measured using 
the methods mentioned earlier. 
HCT116 colorectal carcinoma cells were cultured in Glutamax™ containing Hepes-
buff ered RPMI 1640 medium supplemented with 10% fetal calf serum (Gibco BRL, Paisley, 
UK), 100 U/mL penicillin and 100 μg/mL streptomycin at 37C in a humidifi ed atmosphere 
containing 5% CO2. HCT116 cultures of 60% confl uence were cultured in the presence of 
methimazole (25, 50, and 100 μM) or 0.1% (v/v) MeOH as a solute control. After 5, 24, and 
48 hours, total RNA was extracted using RNA-Bee (Tel-TEST Temco, Inc. Friendswood, TX). 
Relative UGT1A1 mRNA expression levels were measured by real-time RT-PCR using the 
Taqman Universal Master mix and Assay-On-Demand products from Applied Biosystems 
(UGT1A1 assay ID: Hs02511055-s1). The human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH assay ID: 4310884E; VIC/TAMRA) was used for normalization. Reactions 
were run on an ABI PRISM 7900 sequence detector system (Applied Biosystems, Foster 
City, CA) using the following cycling conditions: 50°C for two minutes, 95°C for ten min-
utes followed by 40 cycles of 95°C for 15 seconds, and 60°C for one minute. 
Hek293 cells transfected with pcDNA3 (HEK293/neo) or wild-type BCRP/ABCG2-R482R 
(HEK293/R) were cultured under similar conditions as HCT116. To investigate whether 
ABCG2 activity is aff ected by methimazole, we analyzed the intracellular accumulation 
of mitoxantrone (a well known ABCG2 substrate) in the presence of methimazole. A 
cell suspension of 106 cells of HEK293/neo or HEK293/R in RPMI1640 medium without 
further supplements was incubated in the presence of 3 μM mitoxantrone at 37C for 
90 minutes with or without the addition of 10, 25, 50, 100 μM methimazole or 200 nM of 
the fumitremorgin C analog Ko-143 (ABCG2 inhibitor). The mitoxantrone accumulation 
(fl uorescence intensity) was determined by fl ow cytometry as described previously.13
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RESULTS
The area under the plasma concentration-time curve (AUC) of irinotecan did not diff er 
between the courses with or without methimazole co-treatment (mean 16.1 μg×h/mL; 
Figure 1B; Table 1). However, plasma concentrations of both SN-38 (Figure 1C) and SN-
38G (Figure 1D) were higher during the courses with methimazole. With methimazole, 
the mean SN-38 AUC was 14% higher than without methimazole (125 ng×h/mL versus 
110 ng×h/mL). In the presence of methimazole, the mean SN-38G AUC was 67% higher 
(1,255 ng×h/mL versus 753 ng×h/mL). Consequently, a mean 47% increased relative 
extent of glucuronidation, which is the ratio of SN-38G over SN-38 (mean, 10.1 versus 
6.85), was found during the combination treatment courses. The exposure to the CYP3A 
metabolites APC (mean 3,018 ng×h/mL; Figure 1E) and NPC (mean 32.3 ng×h/mL; Fig-
ure 1F) was not diff erent between the courses with or without methimazole. 
Table 1. Baseline characteristics, pharmacokinetics, chemistry, and toxicities during four treatment 
courses with irinotecan
Irinotecan course 1 2 3 4
Methimazole Yes Yes No No
TSH (0.4-4.3 mU/L)a 0.0 2.6 0.0 0.0
T3 (1.4-2.5 nmol/L)a 1.54 2.11 2.14 2.86
Dose irinotecan (mg) 660 660 660 660
AUC(0-56h) irinotecan (μg×h/mL) 16.6 16.0 15.8 16.0
AUC(0-56h) APC (ng×h/mL) 3,227 2,919 3,028 2,897
AUC(0-8h) NPC (ng×h/mL) 31.9 32.4 32.2 32.5
AUC(0-56h) SN-38 (ng×h/mL) 117 133 106 114
AUC(0-56h) SN-38G (ng×h/mL) 1,301 1,209 728 777
REG 11.1 9.09 6.87 6.82
Bilirubin (0-16 U/L)a 5 6 7 6
Alkaline phosphatase (0-119 U/L)a 189 182 176 152
γ-glutamyltransferase (0-49 U/L)a 60 42 34 33
AST (0-36 U/L)a 20 21 18 16
ALT (0-40 U/L)a 24 23 24 18
Neutrophil nadir (×109/L) 4.7 4.1 4.1 4.0
Diarrhea (grade)b 1 0 0 0
Abbreviations: TSH, thyroid stimulating hormone; T3, active hormone 3,5,3’-triiodothyronine; AUC, area 
under the plasma concentration-time curve; SN-38, active metabolite of irinotecan; SN-38G, detoxifi ed 
metabolite of SN-38; REG, relative extent of glucuronidation; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. 
a Normal values between brackets. For TSH and T3, means of weekly values within a period of three weeks 
are shown.
b Grading according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
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Except for methimazole, co-medication did not change during the studied courses 
and also smoking behavior of the patient (15-20 cigarettes per day) did not change. 
The patient appeared to be wild-type (TA6/TA6) for UGT1A1*28, meaning that UGT1A1 
function was not lowered based on this familiar genetic polymorphism.3 Thyroid hor-
mone levels varied during the assessed courses (Table 1), with a transient but clear 
hyperthyroidism during the fourth course. Nevertheless, a correlation between thyroid 
function and systemic chemotherapy levels could not be established. Irinotecan-related 
toxicity was mild during all courses. The absolute neutrophil count nadir was similar in 
all courses (mean 4.2 ×109/L). 
In the in vitro experiments, simultaneous incubation of human liver microsomes 
with irinotecan and methimazole resulted in a slightly decreased formation of NPC 
and APC (both 16% reduced compared to incubation in the absence of methimazole; 
Figure 2A). Control experiments in which irinotecan was combined with fl uconazole, a 
known potent CYP3A-inhibitor, resulted in a strong inhibition of NPC and APC forma-
tion (78 and 74% inhibition, respectively, compared to experiments in the absence of 
fl uconazole; Figure 2A). No eff ect of methimazole on SN-38 formation was noticed. In 
addition, SN-38G formation did not decrease during the co-incubation of microsomes 
with methimazole and SN-38, while a reduction of 43% was observed during simultane-
ous incubation of SN-38 with the UGT1A1 inhibitor ketoconazole. 
In order to determine whether methimazole is capable of inducing UGT1A1 expres-
sion, a HCT 116 colorectal carcinoma cell line was cultured in the presence of various 
concentrations of methimazole (25-100 μM) for  48 hours after which UGT1A1 mRNA 
levels were measured by quantitative RT-PCR. Figure 2B displays the results of the 
experiment showing a 15 to 18-fold induction of UGT1A1 mRNA levels by methimazole 
compared to untreated control cells. The lowest concentration of methimazole (25 μM) 
gave rise to the highest induction levels after 48 hours, whereas the higher concentra-
tions (50 and 100 μM) already showed strongly elevated UGT1A1 levels after 24 hours 
that seem to return to normal in a concentration-dependent manner after a longer 
incubation period. 
Our in vitro tests in which the transport of mitoxantrone by ABCG2 was studied 
showed that methimazole in concentrations up to 100 μM did not aff ect the effl  ux of 
mitoxantrone. In contrast, the known ABCG2 inhibitor Ko-143 reduced the effl  ux of 
mitoxantrone, thereby causing accumulation of the drug.
DISCUSSION
In the current case, factors known to signifi cantly alter irinotecan pharmacokinetics did 
not change over time, except for the use of methimazole. As a relationship between 
thyroid status and plasma concentrations of chemotherapy was not found, a possible 
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Figure 2. In vitro experiments
A. Eff ects of methimazole (grey bars) and fl uconazole (white bars) on the formation of NPC, APC, and 
SN-38 during co-incubation with irinotecan, and eff ects of methimazole (grey bars) and ketoconazole 
(white bars) on the formation of SN-38G during co-incubation with SN-38. The black bars represent the 
formation of irinotecan metabolites in the absence of any (potential) inhibitor.
B. Methimazole induces UGT1A1 mRNA levels. 
HCT116 cells were cultured in the presence or absence (control) of various concentrations of 
methimazole. At 5 (dark grey bars), 24 (light grey bars) and 48 (white bars) hours total RNA was isolated 
and used to measure UGT1A1 mRNA levels by quantitative RT-PCR (Taqman™). Depicted is the expression 
of UGT1A1 compared to the control UGT1A1 levels (black bars), which are arbitrarily set at 1. Error bars 
indicate 2 x SD (N = 3).
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infl uence of thyroid hormone on UGT1A activity is probably very limited in our case.14 
Therefore, we assume that the intrapatient diff erences in pharmacokinetics found over 
the courses are mainly attributable to methimazole. 
Irinotecan drug concentrations assessed in the courses without methimazole are 
within the low-normal range of literature data6,15,16 possibly due to patients’ smoking 
behavior. As SN-38 levels are only moderately increased, while SN-38G concentrations 
are much higher in the presence of methimazole, our clinical data support the preclini-
cal literature describing combined eff ects of CYP3A inhibition and UGT1A induction by 
methimazole.7,8 However, inhibition of CYP3A was not confi rmed by lower systemic 
concentrations of NPC and APC in the courses with methimazole. In addition, our in vitro 
experiments could not determine an important eff ect of methimazole on CYP3A activ-
ity. Therefore, we have to conclude that the involvement of CYP3A is probably limited in 
the observed pharmacokinetic alterations during methimazole-exposed courses. 
UGT1A induction in turn will lead to increased SN-38G levels, catalyzing SN-38 
transformation into SN-38G. This is expressed by the higher glucuronidation rate dur-
ing the combination treatment. Although the exact mechanism of irinotecan-induced 
delayed-onset diarrhea is unclear, there is consensus that intestinal toxicity is caused by 
local reactivation of SN-38 from SN-38G by β-glucuronidase-producing bacteria in the 
gut.17,18 Therefore, higher SN-38G levels as a result of methimazole co-treatment could 
potentially lead to more intestinal toxicity, since higher systemic SN-38G concentrations 
could cause increased intestinal SN-38 levels, when SN-38G is excreted in the gut and is 
deglucuronidated by intestinal bacteria. This was also shown in a population pharma-
cokinetic model of irinotecan, in which the AUC of SN-38G was correlated with diarrhea 
scores (P < .005).19 In addition, it was shown that co-treatment with the antibiotic neo-
mycin reduces the fecal β-glucuronidase activity and fecal SN-38G/SN-38 ratio, thereby 
reducing the incidence of diarrhea.20 
In our view, it is plausible that the eff ect of higher SN-38G levels in our patient did 
not result in more diarrhea, because this patient already had a low pharmacokinetic and 
toxicity profi le, most likely because of his smoking behavior and wild type UGT1A1*28 
genotype.6 However, in patients who are more prone to toxicity, higher SN-38G levels 
as a result of concomitant methimazole use, could potentially lead to severe diarrhea. 
One cannot formally rule out the possibility that additional mechanisms contribute 
to the observed clinical phenotype. For instance, methimazole might interfere with 
ABC transporters involved in the effl  ux of the irinotecan metabolites, leading to ac-
cumulation of SN-38 and SN-38G. However, there is no literature available indicating 
that methimazole is a substrate or inhibitor of ABC transporters. Moreover, our experi-
ments confi rmed that therapeutic concentrations of methimazole do not aff ect ABCG2-
mediated transport.
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CONCLUSIONS
Although the exact explanation for our fi ndings is subject for further study, the combi-
nation of irinotecan and methimazole might potentially lead to increased toxicity due to 
higher systemic SN-38 and SN-38G concentrations. Reactivation of high concentrations 
SN-38G by bacterial enzymes in the bowel is potentially dangerous in that respect and 
could lead to local toxicity. We therefore advise physicians to be careful in combining 
methimazole with regular irinotecan doses, especially in patients who are prone to 
irinotecan toxicity.
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ABSTRACT
Purpose 
Irinotecan, the prodrug of SN-38, is extensively metabolized by cytochrome P450 3A4 
(CYP3A4). A randomized trial was done to assess the utility of an algorithm for individu-
alized irinotecan dose calculation based on a priori CYP3A4 activity measurements by 
the midazolam clearance test.
Experimental design 
Patients were randomized to receive irinotecan at a conventional dose level of 350 
mg/m2 (group A) or doses based on an equation consisting of midazolam clearance, 
γ-glutamyltransferase, and height (group B). Pharmacokinetics and toxicities were ob-
tained during the fi rst treatment course.
Results 
Demographics of 40 evaluable cancer patients were balanced between both groups, 
including UGT1A1*28 genotype and smoking status. The absolute dose of irinotecan 
ranged from 480 to 800 mg in group A and 380 to 1,060 mg in group B. The mean abso-
lute dose and area under the curve of irinotecan and SN-38 were not signifi cantly diff er-
ent in either group (P > .18). In group B, the interindividual variability in the area under 
the curve of irinotecan and SN-38 was reduced by 19% and 25%, respectively (P > .22). 
Compared with group A, the incidence of grades 3 to 4 neutropenia was > 4-fold lower 
in group B (45 versus 10%; P = .013). The incidence of grades 3 to 4 diarrhea was equal in 
both groups (10%). 
Conclusions 
Incorporation of CYP3A4 phenotyping in dose calculation resulted in an improved pre-
dictability of the pharmacokinetic and toxicity profi le of irinotecan, thereby lowering the 
incidence of severe neutropenia. In combination with UGT1A1*28 genotyping, CYP3A4 
phenotype determination should be explored further as a strategy for the individualiza-
tion of irinotecan treatment.
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INTRODUCTION
In 1996, the topoisomerase-I inhibitor irinotecan received accelerated approval in 
the United States for the second-line treatment of patients with metastatic colorectal 
carcinoma. Currently, irinotecan is approved as a single agent as well as in combination 
with other drugs (i.e., fl uorouracil, oxaliplatin, and bevacizumab) in diff erent fi rst-line 
and second-line regimens for the treatment of this disease.1-4 
Several enzymes and drug transporters are involved in the elimination of irinotecan, 
including members of the cytochrome P450 3A (CYP3A) and uridine diphosphate gluc-
uronosyltransferase 1A (UGT1A) families, both of which infl uence exposure to the active 
metabolite, SN-38 (Figure 1).5 Because the expression and function of these proteins 
could be aff ected by numerous environmental and genetic factors, the pharmacokinet-
ics of irinotecan and its metabolites vary greatly between patients.5,6 
Like most other cytotoxic anticancer agents, irinotecan has a narrow therapeutic 
window. Therefore, the large interindividual pharmacokinetic variability may result in 
overtreatment with unacceptable side eff ects in some patients and in undertreatment 
with diminished therapeutic eff ects in others. The conventional dose calculation of 
irinotecan is based on an individual’s body surface area (BSA), although this approach 
does not result in reduced pharmacokinetic variability (Figure 2A) compared with a fl at-
fi xed dose.7,8 New dosing strategies that take the pharmacologic profi le of irinotecan in 
 
 
 
 
 
 
 
 
 
 
Figure 1. Metabolism of irinotecan
Irinotecan is converted into its 100 to 1,000 times more active metabolite SN-38 by human 
carboxylesterases type 1 and 2, which are predominately found in the liver. The affi  nity for this reaction 
is low, because only ~3% of irinotecan is converted into SN-38. SN-38 is glucuronidated by UGT1A into 
the inactive metabolite SN-38G. β-glucuronidase-producing bacteria can reverse this reaction in the 
intestines, reactivating SN-38, and causing the dose-limiting toxicity diarrhea. Competing with the 
formation of SN-38 is the CYP3A-mediated inactivation of irinotecan into the metabolites APC and NPC. 
Abbreviations: APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin; 
CES, carboxylesterases; CYP3A, cytochrome P450 3A isoforms (3A4/3A5); M4, fourth unspecifi ed 
metabolite of irinotecan; NPC, 7-ethyl-10-(4-amino-1-piperidino)-carbonyloxycamptothecin; SN-38, 
7-ethyl-10-hydroxycamptothecin; SN-38G, glucuronide form of SN-38; UGT1A, uridine diphosphate 
glucuronosyltransferase 1A isoforms (1A1/1A7/1A9).
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the individual patient into account could potentially replace BSA-based dosing, if this 
would lead to a reduction in the pharmacokinetic variability. Ideally, this should prevent 
the occurrence of highly unpredictable severe toxicities associated with irinotecan 
administration, such as neutropenia and late-onset diarrhea, and should result in a 
maximal antitumor response in each patient.
Thus far, new dosing strategies have mainly focused on polymorphisms aff ecting the 
expression of enzymes involved in the metabolism of SN-38, such as the UGT1A1*28 
polymorphism.9-11 It should be pointed out, however, that the expression of many en-
zymes and transporters of relevance to irinotecan, is also infl uenced by environmental 
factors, such as co-medication, complementary and alternative medicine, disease status, 
and lifestyle.12 Therefore, dose-individualization strategies should not solely focus on 
inherited variables.
Figure 2. Development and validation of a new dosing equation for irinotecan
A. The relationship between BSA and irinotecan clearance in a cohort of 190 patients.18 Conclusion: BSA-
based dosing does not reduce the interindividual pharmacokinetic variability of irinotecan. 
B-C. Correlation between the equation-based predicted clearance and the measured irinotecan clearance 
in the former study (B, N = 30),17 and in the current study (C, N = 20). 
Abbreviations: CL, clearance; N, number; pred, predicted.
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From drug interaction studies involving enzyme inducing and enzyme inhibiting 
compounds, such as St. John’s wort and ketoconazole, it is known that the CYP3A4 
pathway plays a crucial role in the inactivation of irinotecan into a number of inactive, 
oxidative metabolites.13,14 Because CYP3A4 activity can be infl uenced by many factors, 
and is largely variable between patients,15 it has been proposed that a priori assess-
ment of the functional activity of CYP3A4, for instance by using probe drugs such as 
midazolam or erythromycin,16 may aid in irinotecan dose calculation. Previously, we 
found that CYP3A4 activity as determined by midazolam pharmacokinetics was highly 
correlated with irinotecan clearance.17
We developed a new dosing equation for irinotecan treatment by using linear re-
gression analysis to identify clinical parameters that could predict irinotecan clearance. 
Here, we report on a randomized clinical trial in which we compared classic BSA-based 
dosing with individualized irinotecan dose calculation on the basis of an equation that 
incorporated an individual’s CYP3A4 activity, height, and γ-glutamyltransferase.
MATERIALS AND METHODS
Patients
Patients were included according to the following inclusion criteria: (a) a histologically or 
cytologically confi rmed diagnosis of any form of metastatic cancer which was thought 
to be sensitive to irinotecan treatment; (b) age ≥ 18 years; (c) a WHO performance score 
of < 2; and (d) adequate hematologic, renal, and hepatic function as determined within 
two weeks before inclusion and repeated one day prior to the start of treatment. An 
additional criterion was used for baseline γ-glutamyltransferase, (< 200 units/L, which 
is approximately fi ve times the upper limit of normal) because it was one of the three 
parameters on which the dosing equation was based, and this was the upper limit that 
was seen in the earlier study upon which the equation was formulated.17 
During the study period, starting three weeks before irinotecan administration, 
patients were not allowed to use grapefruit or grapefruit juice, St. John’s wort or any 
other known inhibitor and/or inducer of CYP3A4. Use of temazepam was prohibited as 
well, because this compound was used as the internal standard for the midazolam assay. 
Other specifi c exclusion criteria included (a) any form of anticancer treatment within 
four weeks of the start of irinotecan administration, (b) unresolved bowel obstruction 
or chronic colic disease, and (c) any form of illness that would prohibit the process of 
understanding and giving of informed consent. All patients gave written informed 
consent and the local institutional review boards approved the clinical protocol, which 
was written in accordance with the declaration of Helsinki. 
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Treatment
Before the start of treatment, baseline toxicities were recorded, a physical examination 
took place, and bone marrow, renal, and hepatic function were obtained using routine 
laboratory analyses. Patients were randomized to either receive a BSA-based dose of 
350 mg/m2 or a dose calculated from an equation that took into account the height, 
baseline γ-glutamyltransferase, and midazolam clearance of the patient. This equation 
was derived from data obtained previously in 30 patients,17 using regression analysis 
in Stata version 8.2 (Stata Corp.). All patient-related factors that could possibly aff ect 
irinotecan clearance were taken into account, and included age, height, weight, BSA, 
baseline blood cell counts, measures of liver and renal function, and genetic variation 
in genes encoding ATP-binding cassette drug transporters and drug-metabolizing en-
zymes involved in the elimination pathway of irinotecan. 
The fi nal equation for irinotecan clearance was: 0.0325 × midazolam clearance (mL/
min) − 0.0396 × γ-glutamyltransferase (units/L) + 27.180 × height (m) − 31.926.
This equation explained  80% of the variability in irinotecan clearance (Figure 2B), 
whereas BSA explained only 21% (data not shown). A dose for each patient in the equa-
tion group was calculated by multiplying the predicted irinotecan clearance by 22.157 
(μg×h/mL), which was the mean area under the curve of irinotecan observed previously, 
and this value was arbitrarily defi ned as the target measure of systemic exposure.17 To 
eliminate age as a potential confounding variable, patients were stratifi ed and matched 
according to age (≤ 55 versus > 55 years) within each treatment group and within each 
participating institution. Application of premedication and treatment of gastrointestinal 
toxicity were done as described previously.18
Pharmacologic studies
All patients underwent a midazolam clearance test seven or eight days prior to the start 
of irinotecan treatment. A midazolam dose of 0.025 mg/kg was injected i.v. as a bolus, 
followed by a running infusion of 0.9% saline over a 30-second period. Blood sample 
collection, analytic measurements of midazolam, irinotecan and SN-38 in plasma, and 
pharmacokinetic parameter calculations were done as described previously, with minor 
modifi cation.17 Following separate consent, DNA was obtained from all patients and 
analyzed for the UGT1A1*28 variant using a LightCycler method,19 with modifi cations.17
Toxicity evaluation
Patients were seen weekly at the outpatient clinic for follow-up, which included a physi-
cal examination and routine hematologic, renal, and hepatic laboratory analyses. All 
side eff ects, including leukopenia, neutropenia, and late-onset diarrhea were graded 
using the National Cancer Institute Common Terminology Criteria for Adverse Events 
version 3.0.20
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Statistical considerations
Statistical calculations were done using SPSS version 14.0 (SPSS Inc.) and Stata version 
8.2 (Stata Corp.). An estimation of the SEM of the interindividual variability was obtained 
as described.21 Based on an estimated mean interindividual variability in irinotecan area 
under the curve of 30% with an SD of 22.6 in patients receiving a dose of 350 mg/m2, 
a sample size of 20 patients per treatment group was necessary to detect a 50% lower 
variability with a two-sided P = .05 and a power of 80%. Diff erences in categorical data 
were analyzed using χ2-test. 
Diff erences in interindividual pharmacokinetics and all other continuous variables 
in both groups were calculated using a Student’s t-test. Root mean square error, mean 
predictive error, and Pearson’s correlation coeffi  cient were used to relate two continu-
ous variables.22 All data are presented as means with SD or 95% confi dence intervals in 
parentheses, unless stated otherwise. P < .05 values were considered signifi cant.
RESULTS
Patient characteristics
Forty-fi ve cancer patients were randomized between September 2005 and August 
2007 to receive a BSA-based dose or an equation-based irinotecan dose, and received 
irinotecan treatment in accordance with the protocol. Of these, fi ve patients were not 
evaluable for analysis; three due to technical problems with blood sampling, one was 
lost to follow-up, and one had an elevation of γ-glutamyltransferase induced by alcohol 
abuse at the start of treatment. The remaining 40 patients (22 males and 18 females) 
with a mean age of 58 (range, 27-70) were evaluable for analysis. No signifi cant diff er-
ences were seen in age, gender, smoking status, UGT1A1*28 genotype, and number of 
previous chemotherapeutic treatments between both groups (Table 1).
Pharmacokinetics of midazolam
CYP3A4 activity, as determined by midazolam clearance, varied  6-fold (range, 203 
1,257 mL/min), with a mean of 698 mL/min (95% confi dence interval, 609-786 mL/min). 
These data are consistent with previously reported values.17,23,24
Pharmacokinetics of irinotecan
The mean absolute dose was not signifi cantly diff erent between either group (650 versus 
698 mg; P = .28; Figure 3A). However, the range of doses was much broader in the group 
that received the dose calculated by the equation (480-800 versus 380-1,060 mg). If the pa-
tients from the equation group would have been dosed on BSA, this would have resulted 
in a slightly lower mean dose of 675 mg, and a range of 494 to 830 mg for this group. 
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There were no diff erences in the mean area under the curve of irinotecan and SN-38 
between both groups of patients (P > .18; Figure 3B and C). In the group receiving the 
dose calculated by the equation, the interindividual variability (expressed by SD/mean) 
in the area under the curve was 19% lower for irinotecan (31% versus 25%; P = .35) and 
25% lower for SN-38 (45% versus 34%; P = .22), whereas the mean interindividual vari-
ability in the administered dose was signifi cantly higher in this group (11% versus 26%; 
P = .002). 
Table 1. Patient characteristics
Characteristicsa BSA group (N = 20) Equation group (N = 20) Pb
Sex
 Male 11 (50%) 11 (50%)
 Female 9 (50%) 9 (50%)
Age (years)c 57 (27-70) 55 (27-69) .60d
Height (m)c 1.74 (1.52-1.85) 1.75 (1.54-1.87) .83d
γ-glutamyltransferase (units/L)c 76 (57) 61 (46) .34d
Smoking statuse .63
 No 16 (48%) 17 (52%)
 Yes 3 (60%) 2 (40%)
Previous chemotherapy .72
 0-1 14 (48%) 15 (52%)
 ≥ 2 6 (55%) 5 (45%)
Tumortype .18
 Colorectal 3 (43%) 4 (57%)
 Gastric 2 (40%) 3 (60%)
 Pancreas 2 (50%) 2 (50%)
 Miscellaneousf 13 (54%) 11 (46%)
UGT1A1*28 genotypeg .79
 6/6 9 (56%) 7 (44%)
 6/7 8 (44%) 10 (56%)
 7/7 1 (50%) 1 (50%)
a Data are presented as absolute numbers with percentages in parentheses, unless stated otherwise. 
b P values result from χ2-test, unless stated otherwise. 
c Data presented as mean with range or SD in parentheses. 
d P values resulting from two-sample t-tests. 
e N = 38 (smoking status unknown in two patients). 
f Including sarcoma (4), esophageal carcinoma (3), breast cancer (3), (adeno)carcinoma of unknown 
primary (2), jejunal carcinoma (2), small cell lung cancer (2), urothelial carcinoma (2), melanoma (2), 
cholangiocarcinoma (1), ovarian carcinoma (1), medulloblastoma (1), and head and neck cancer (1). 
g N = 36 (genotype unknown in four patients). 
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The predicted clearance of irinotecan calculated by the equation was correlated with 
the observed clearance in the group receiving the dose calculated by the equation (root 
mean square error, 21.8%; mean predictive error, 4.08%, R2 = .56; P < .001; Figure 2C).
Toxicities of irinotecan
The incidence of grades 3 to 4 neutropenia was more than four times lower in the pa-
tients receiving the equation-based dose (45% versus 10%; P = .013; Figure 4). Similarly, 
the incidence of grades 3 to 4 leukopenia was three times lower in this group (45% ver-
sus 15%; P = .038). In the group receiving a BSA-based dose, three patients experienced 
febrile neutropenia (15%), whereas in the other group, none of the patients experienced 
this dose-reducing side eff ect. Although not reaching statistical signifi cance, a lower 
mean nadir white blood cell count (66% versus 45%; P = .10) and nadir absolute neu-
trophil count (80% versus 55%; P = .10) were found in the group receiving an irinotecan 
dose determined by the equation. No diff erences were seen in the incidence of severe 
diarrhea (grades 3-4), which was 10% in both groups.
DISCUSSION
We developed a new dosing algorithm for irinotecan treatment, which was based on an 
individual’s CYP3A4 activity, γ-glutamyltransferase, and height and was prospectively 
compared with BSA-based dosing in a randomized trial. We found that the predicted 
irinotecan clearance according to the equation was correlated (with little bias and good 
accuracy) with the measured clearance in the group that received the equation-based 
dose. As a result, the interindividual pharmacokinetic variability of irinotecan and its 
active metabolite SN-38 were 19% to 25% lower in the equation-based dosing group, 
Figure 3. Interindividual variability in the dose and pharmacokinetics of irinotecan
Range, means, and interindividual variability of the administered dose (A), irinotecan area under the 
plasma concentration-time curve (B), and SN-38 area under the plasma concentration time-curve (C) in 
the BSA group (left) and the equation group (right).
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whereas the dose range was substantially broader in this group. In line with the known 
association between irinotecan pharmacokinetics and drug-related toxicities,5,7,18 
a > 4-fold reduction of severe myelosuppression was observed in the equation-based 
dosing group as compared with the other group. 
In our study, we excluded all patients who were using known CYP3A inducers and/
or inhibitors which could not be replaced by other medicines because of the potential 
hazard or treatment failure when giving these patients a (full) BSA-based dose. However, 
in clinical practice, patients who are taking this medication would probably benefi t even 
more from dosing on the basis of our CYP3A phenotype-based equation. 
It is noteworthy that two patients in the equation-based dosing group were treated 
with an absolute irinotecan dose of 1,060 mg. This is an extremely high dose because 
the standard dose for the three-weekly schedule was 350 mg/m2, suggesting that only 
patients with a BSA of > 3.0 m2 would have received a similar absolute dose, which is usu-
ally only the case for morbidly obese individuals. Even under these circumstances, most 
physicians would not prescribe such a high dose because doses are typically capped 
at a BSA of 2.0 m2.25 In the current study, both patients received a total of six courses 
of irinotecan at a dose of 1,060 mg in each course without experiencing any toxicity 
higher than grade 1. It is of interest to note that one of these patients was even hetero-
zygous for the UGT1A1*28 allele, and may therefore have been genetically predisposed 
to an increased risk of experiencing severe toxicity after irinotecan treatment.26,27 This 
illustrates the feasibility of administering higher doses of irinotecan than the approved 
BSA-based dose in subgroups of patients that are at low risk for experiencing severe side 
Figure 4. Toxicities of irinotecan
Bargraph showing that the incidence of severe (grades 3-4) neutropenia (according to the Common 
Terminology Criteria of Adverse Events) was higher in the BSA group (left) when compared with the 
equation group (right; P = .013).
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eff ects. The selection of such patients might also increase the potential clinical benefi t 
of irinotecan, whereas the administration of lower doses, based on our equation, to pa-
tients who cannot tolerate standard doses might decrease the occurrence of potentially 
life-threatening adverse eff ects. 
One could speculate that the response to treatment might be negatively aff ected by 
the use of a dosing algorithm that is associated with a reduced incidence of severe side 
eff ects. However, it should be pointed out that the systemic exposure to both irinotecan 
and SN-38 was equal in both groups, and that overall, the administered doses were even 
slightly higher in the equation-based dosing group, making this hypothesis unlikely. In 
addition, if the patients from the equation group were dosed on BSA, this would have 
resulted in a lower mean absolute dose. Our view is that by predicting irinotecan expo-
sure in the individual patient, those patients who were at risk for severe toxicities based 
on their phenotypic profi le had received a lower dose, whereas those patients with 
a more favorable profi le had received a higher dose. The average administered dose 
and exposure to irinotecan in the whole group remained equal, but by administering 
a tailored dose to each individual, the overall toxicity in the group was reduced. Ad-
ditional investigation into the infl uence of equation-based dosing on antitumor activity 
(response and survival) of irinotecan is required to support this theory. 
In addition to its role in irinotecan dosing, CYP3A4 phenotyping may also be valuable 
in dose calculations of other anticancer drugs with narrow therapeutic windows that are 
extensively metabolized by CYP3A4, such as docetaxel,28,29 sunitinib,30 and gefi tinib.31 
Indeed, Yamamoto et al. have shown the potential clinical eff ect of applying CYP3A4-
phenotyping into the dose calculation of docetaxel.32 The applied equation consisted 
of urinary concentrations of 6β-hydroxycortisol as a measure of CYP3A4 activity, α1-
acid glycoprotein, transaminases and age, and resulted in a reduced interindividual 
pharmacokinetic variability when compared with BSA-based dosing. However, before 
these kinds of dose calculations could be clinically implemented, CYP3A4 phenotyping 
tests should become routinely available in daily clinical practice, and become less time-
consuming and less invasive. Further refi ning of these tests is warranted, for example, 
by developing strategies for determining midazolam clearance that involve a reduced 
number of blood samples, and by specifi cally identifying an optimal CYP3A4 probe for 
each agent under investigation.33
The small population that was investigated in our study could have accounted for the 
fact that the 19% to 25% diff erences in interindividual pharmacokinetic variability were 
not statistically signifi cant. Yet, these decreases may have clinical relevance. Importantly, 
the study showed a signifi cant change in grades 3 to 4 hematologic toxicity in favor of 
the equation-based dose calculation. However, independent confi rmation of our study 
results is necessary, as well as a demonstration that the antitumor response is equal in 
both groups or higher when the irinotecan dose is calculated according to the equation. 
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Because irinotecan is often administered in combination regimens; at lower doses, and 
at a higher frequency than the regimen that was investigated in our study, it is also 
necessary to investigate the relevance of equation-based dose calculation in other 
irinotecan schemes before implementing this dosing strategy. 
In conclusion, the current study supports the feasibility of using CYP3A4 activity, 
height, and baseline γ-glutamyltransferase measurements to individualize irinotecan 
dose calculation. The application of this methodology was associated with a reduced 
interindividual pharmacokinetic variability, although it was not statistically signifi cant. 
The incidence of severe myelosuppression was signifi cantly reduced in the equation-
based dosing group compared with the BSA-based dosing strategy. In combination with 
UGT1A1*28 genotyping, CYP3A4 phenotype determination should be explored further 
as a strategy to identify patients that are at risk for experiencing severe side eff ects fol-
lowing irinotecan administration.34
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SUMMARY
Although irinotecan can be very eff ective in the treatment of advanced colorectal 
cancer, it still is a notorious drug to some medical oncologists, due to its unpredictable 
side eff ects, mainly diarrhea and neutropenia. These side eff ects can be very severe and 
sometimes even lethal. Years of research have elucidated the complex metabolism of iri-
notecan, which involves several phase I and II enzymes and drug transporters (Chapter 
1). In addition, many attempts have been made to explain and reduce the interpatient 
variability in the pharmacokinetics of irinotecan, thereby improving effi  cacy and reduc-
ing toxicity. Also, many eff orts were made to directly decrease the intestinal toxicity. In 
this thesis, several pharmacological aspects of irinotecan treatment were investigated, 
with the ultimate goal to optimalize and personalize irinotecan therapy.
Despite the knowledge of the causative role of smoking to several types of cancer, 
little is known about the eff ects of smoking on the outcome of anticancer treatment. 
This is striking, given the fact that almost 30% of cancer patients still smoke during 
treatment. Several constituents of cigarette smoke are known to interact with certain 
drug-metabolizing enzymes, and may therefore infl uence the pharmacokinetics of 
anticancer drugs, potentially resulting in altered toxicity and effi  cacy of these drugs. In 
Chapter 2, the eff ects of smoking on the pharmacokinetics and toxicities of irinotecan 
were investigated in 190 cancer patients treated with single agent irinotecan. Twenty-six 
percent of the patients were smoking during their anticancer treatment. Patients who 
smoked during irinotecan treatment had a signifi cantly lower exposure to irinotecan 
and in particular to the active metabolite SN-38. The area under the curve of SN-38 was 
40% lower in smokers. The incidence and severity of leukopenia and neutropenia were 
also lower in smokers. The combination of a decreased exposure to irinotecan and the 
active metabolite SN-38, and less severe toxicity in smokers, suggests that patients who 
smoke during their irinotecan treatment have an increased risk of treatment failure.
While only a limited number of studies have been performed on the infl uence of life-
style factors on anticancer treatment, a lot more attention has been paid to the role of 
polymorphisms in genes coding for metabolizing enzymes and drug transporters that 
are involved in the metabolism of chemotherapeutic drugs. However, genetic variation 
in genes coding for proteins that are linked to pharmacodynamic outcome could be of 
importance too. We investigated this for mannose binding lectin (MBL); a protein that 
plays an important role in the innate immune response. Polymorphisms in the MBL2 
gene aff ect MBL expression and patients with hematological malignancies having geno-
types that are related to low MBL levels, have been associated with an increased risk 
of infections after chemotherapy. However, these results are inconsistent and data on 
patients with solid tumors are lacking. Chapter 3 describes the eff ect of polymorphisms 
in the MBL2 gene on irinotecan-induced febrile neutropenia in 133 patients with solid 
tumors. Patients with high MBL promoter genotypes and haplotypes had a signifi cantly 
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higher incidence of neutropenic fever. This could be explained by an increased activa-
tion of the complement system in patients with high MBL genotypes, as compared to 
patients with low MBL genotypes.
Although a substantial part of the administered dose of irinotecan is recovered in 
urine, little data is available on the association between renal function and the disposition 
of irinotecan. In Chapter 4, the eff ects of renal function on irinotecan pharmacokinetics 
and toxicities were investigated in 187 patients treated with single agent irinotecan. The 
creatinine clearance was calculated by the Cockcroft-Gault equation and patients were 
categorized according to renal function. No infl uence on irinotecan pharmacokinetics 
over the studied range of renal functions was seen. However, categorized renal function 
was related to hematological toxicity. The incidence of severe neutropenia (grade 3-4) 
was signifi cantly higher in patients with decreased renal function, particularly in non-
smoking patients. It is therefore recommended to take renal function into account in 
the dosing of irinotecan.
Next to lifestyle factors and comorbidity, the use of concomitant medication that 
infl uence metabolizing enzymes and drug transporters may play an important role in 
aff ecting drug therapy. It is known that drug-drug interactions are a major source of 
treatment failure by reducing effi  cacy and increasing toxicities. In the next chapters of 
this thesis, the infl uence of co-medication on the pharmacokinetics and toxicities of 
irinotecan was investigated. 
Chapter 5 describes a drug-drug interaction study between irinotecan and the com-
monly prescribed proton pump inhibitor omeprazole. The in vitro study showed that 
omeprazole induces the enzyme UGT1A1 and reduces the formation of the inactive 
irinotecan metabolites, APC and NPC, in the same proportion as the known CYP3A in-
hibitor fl uconazole. In the clinical study, fourteen patients were treated with two cycles 
of irinotecan, one with and one without omeprazole. In vivo no eff ects of omeprazole 
on the pharmacokinetics and toxicities of irinotecan were seen. A standard dose of 
omeprazole can therefore be safely administered in combination with a three-weekly 
schedule of single agent irinotecan. 
In Chapter 6 we investigated the eff ect of methimazole on the pharmacokinetics and 
toxicities of irinotecan in a patient who was treated with four cycles of irinotecan; two 
with and two without methimazole. Although no eff ect was seen on the pharmacokinet-
ics of irinotecan itself, SN-38 exposure was higher in the cycles combined with methima-
zole. Strikingly, SN-38G exposure was almost doubled in the cycles with methimazole, 
suggesting an induction of UGT1A1, which was confi rmed by additional in vitro studies. 
As higher intestinal SN-38G levels can be (re-)activated locally into SN-38, the combina-
tion of methimazole and irinotecan may result in increased intestinal toxicity.
Currently many factors are known to contribute to the large interpatient variability 
in the pharmacokinetics of irinotecan. However, body surface area (BSA)-based dosing 
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of irinotecan is still largely practised worldwide, despite the knowledge that BSA-based 
dosing does not result in a reduction of pharmacokinetic variability. To optimize and 
truly personalize irinotecan treatment, new dosing algorithms which incorporate fac-
tors that infl uence irinotecan pharmacokinetics, should be developed. 
Therefore, in Chapter 7 a new dosing equation based on multivariate analysis of 
pharmacokinetic data was developed to reduce the interpatient variability in pharma-
cokinetics and toxicities. All known factors possibly aff ecting irinotecan clearance were 
taken into account, including age, height, weight, BSA, baseline blood cell counts, liver 
and renal function, and genetic variations in the UGT1A1 gene. The resulting dosing algo-
rithm was based on three patient characteristics: height, baseline γ-glutamyltransferase 
and CYP3A activity, as determined by the clearance of the CYP3A probe midazolam 
(Figure 1). These three parameters together explained almost 80% of the variability in 
irinotecan clearance. This is extremely high in comparison to the variability explained 
by BSA, which is only 20%. The new dosing equation was prospectively compared with 
regular BSA-based dosing in a randomized study with 40 cancer patients. Although 
the range of doses administered to the patients in the ‘equation-group’ (380-1,060 mg) 
was much wider than in the BSA-group (480-800 mg), dosing with the new equation 
resulted in a lower interpatient variability of the exposure to irinotecan and SN-38, and 
a signifi cantly lower incidence of severe neutropenia.
Probe drug
(midazolam)
PK
Probe-drug
Drug PK
Patient characteristics Prediction
Overlapping 
metabolic route
(irinotecan) Drug
Figure 1. Phenotyping
By determining the pharmacokinetics (PK) of a drug that has an overlapping metabolic route with the 
drug of interest, one can predict the pharmacokinetics of this drug. It takes into account not only the 
genetic profi le, but also other characteristics of the patient that infl uence the metabolism of a drug. 
The drug that is used to predict the pharmacokinetics of the other drug is called a probe drug. Just like 
irinotecan, midazolam is metabolized by CYP3A. By determining the pharmacokinetics of midazolam in 
the patient prior to irinotecan infusion one can predict the CYP3A activity of that patient and thereby 
predict the pharmacokinetics of irinotecan.
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CONCLUSION
This thesis introduces new factors that infl uence irinotecan pharmacokinetics and 
toxicities. In addition, a new dosing strategy for individualized treatment of irinotecan 
was proposed on the basis of CYP3A phenotyping. Phenotyping has the potential to 
be helpful in individualized irinotecan dosing, as it takes into account several patient 
characteristics that infl uence the activity of metabolizing enzymes. However, it is quite 
labor-intensive and requires a good interplay between the clinic and well-equipped 
laboratories. For this reason, simplifi ed strategies should be developed that require 
minimal blood sampling. In addition, pharmacokinetic optimization of irinotecan dos-
ing, for instance by using therapeutic drug monitoring, could be an option. 
In the era of personalized medicine, there still is some way to go for irinotecan. Al-
though new factors can be added to the toolbox of individualized irinotecan treatment, 
many undiscovered factors remain. The most important question yet to be answered is 
how the interplay of all currently known factors relates to treatment outcome of irinote-
can. Although it is a generally assumed that outcome is related to drug exposure, solid 
data on these relationships in the fi eld of chemotherapy are lacking. 
Additional small studies will likely not add useful information. To answer the remain-
ing questions on interplay, research groups should collaborate more and exchange 
databases of irinotecan pharmacokinetic, pharmacodynamic, and pharmacogenetic 
studies and phase III trials, combine them to create large patient populations, and sub-
sequently perform multivariate and meta-analyses. Finally, pharmacological research 
should be incorporated in large phase III and phase IV studies, preferably with limited 
sampling models to investigate and confi rm exposure-outcome relationships.
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SAMENVATTING
Hoewel het geneesmiddel irinotecan goed werkzaam is bij de behandeling van uit-
gezaaide dikke darmkanker (colorectaal carcinoom), is het impopulair bij sommige 
internisten-oncologen. Het medicijn veroorzaakt namelijk een aantal onvoorspelbare 
bijwerkingen, met name diarree en een tekort aan witte bloedcellen (leukopenie en 
neutropenie). Deze bijwerkingen kunnen zeer ernstig zijn en in enkele gevallen zelfs 
dodelijk. 
Onderzoek naar de werking van geneesmiddelen, oftewel farmacologisch onderzoek, 
bestaat uit twee verschillende onderdelen: het bestuderen van enerzijds de farmacoki-
netiek en anderzijds de farmacodynamiek van een medicijn. De farmacokinetiek be-
schrijft hoe het medicijn door het lichaam wordt verwerkt en bestaat uit vier processen: 
opname van het geneesmiddel na toediening (absorptie), de verdeling over het lichaam 
(distributie), de omzetting in andere werkzame of niet-werkzame stoff en (metabolisme) 
en de uitscheiding van het medicijn via de nieren of darmen (eliminatie). Deze processen 
tezamen bepalen de blootstelling aan een medicijn gedurende een bepaalde periode. 
Door het meten van concentraties van het medicijn in het bloed van een patiënt op 
bepaalde tijdstippen, kan een grafi ek worden gemaakt waarin de concentraties worden 
uitgezet in de tijd. De oppervlakte onder deze tijd-concentratie grafi ek noemen we AUC 
(area under the curve) en is een maat voor de blootstelling aan het medicijn gedurende 
een bepaalde tijd. De andere tak van de farmacologie, de farmacodynamiek, beschrijft 
wat het medicijn met het lichaam doet en bestaat uit de werking (eff ectiviteit) en de 
bijwerkingen (toxiciteit). Chemotherapeutica (anti-kankermedicijnen) hebben een 
zogenoemde smalle therapeutische breedte. Dat wil zeggen dat het doseren van het 
medicijn zeer nauw luistert, omdat de dosis die nodig is om het middel werkzaam te 
laten zijn en de dosis waarbij bijwerkingen optreden heel dicht bij elkaar liggen. Als er 
te weinig van het medicijn wordt gegeven en er dus een te lage blootstelling is, is er 
onvoldoende werking; als er teveel wordt gegeven en er dus een te hoge blootstelling 
is, kunnen er (ernstige) bijwerkingen optreden. 
Jaren van farmacologisch onderzoek hebben het complexe metabolisme van irino-
tecan grotendeels opgehelderd. Bij het metabolisme van irinotecan zijn verschillende 
eiwitten betrokken; metaboliserende enzymen die zorgen voor de omzetting van iri-
notecan in werkzame en niet-werkzame stoff en en transport-eiwitten die zorgen voor 
de opname en uitscheiding van irinotecan in en door verschillende organen (Figuur 1).
Irinotecan is een zogenoemde ‘pro-drug’, dat wil zeggen dat het in het lichaam moet 
worden omgezet in een andere stof voordat het werkzaam is. Deze werkzame stof van 
irinotecan heet SN-38.
Er is veel verschil in de werking en bijwerkingen van irinotecan tussen patiënten. Bij 
de ene patiënt werkt het medicijn heel goed en zijn er nauwelijks bijwerkingen, bij de 
andere patiënt werkt het medicijn nauwelijks of zijn er ernstige bijwerkingen. Naast 
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het onderzoek naar het metabolisme van irinotecan zijn er vele pogingen gedaan om 
de verschillen tussen patiënten (inter-patiënt variabiliteit) in de farmacokinetiek te 
verklaren en deze verschillen tussen patiënten te verminderen. Hiermee zou de werk-
zaamheid van het medicijn worden verbeterd en de bijwerkingen worden verminderd. 
Ook zijn er verschillende pogingen gedaan om de door irinotecan veroorzaakte diarree 
rechtstreeks te verminderen in plaats van op een indirecte manier door de verschillen 
in blootstelling te verminderen. In dit proefschrift zijn verschillende farmacologische 
aspecten van irinotecan behandeling onderzocht, met als uiteindelijk doel de behande-
ling met irinotecan te optimaliseren door voor iedere patiënt afzonderlijk een ideale 
dosering te bepalen die zorgt voor een optimale werking met minimale bijwerkingen.
Hoewel het algemeen bekend is dat roken een rol speelt in het veroorzaken van 
verschillende vormen van kanker, is er weinig bekend over het eff ect van roken op de 
werkzaamheid van een anti-kankerbehandeling met chemotherapie. Dit is opvallend, 
gezien het feit dat bijna 30% van de kankerpatiënten rookt tijdens de behandeling. Van 
verscheidene bestanddelen van sigarettenrook is bekend dat ze een invloed hebben op 
bepaalde metaboliserende enzymen en daarmee de farmacokinetiek van anti-kanker-
medicijnen mogelijk kunnen beïnvloeden. Door een verandering in de blootstelling aan 
het medicijn (door een veranderd metabolisme) kunnen er veranderingen optreden in 
de bijwerkingen en werkzaamheid. In Hoofdstuk 2 is het eff ect van roken op de farma-
cokinetiek en bijwerkingen van irinotecan onderzocht bij 190 kankerpatiënten die wer-
den behandeld met irinotecan. Zesentwintig procent van de patiënten rookte tijdens 
hun anti-kankerbehandeling met irinotecan. Rokende patiënten hadden een signifi cant 
lagere blootstelling aan irinotecan en vooral aan de werkzame stof SN-38. De AUC van 
SN-38 was 40% lager bij de rokers. Daarnaast was het optreden en de ernst van leuko-
penie en neutropenie (een tekort aan witte bloedcellen) lager bij rokende patiënten. De 
combinatie van een lagere blootstelling aan irinotecan en de werkzame stof SN-38, en 
minder ernstige bijwerkingen bij rokers, suggereert dat patiënten die roken tijdens hun 
irinotecan-behandeling een verhoogd risico hebben op het falen van de behandeling. 
Terwijl er slechts weinig onderzoek is gedaan naar de invloed van levensstijl op de 
werkzaamheid van anti-kankerbehandelingen, is er veel meer aandacht besteed aan 
de rol van variaties (polymorfi smen) in genen die de aanmaak van metaboliserende 
enzymen en transport-eiwitten reguleren. Echter, variaties in andere genen, zoals genen 
die de aanmaak reguleren van eiwitten die te maken hebben met farmacodynamische 
factoren, zouden ook belangrijk kunnen zijn. We hebben dit onderzocht voor mannose-
bindend lectine (MBL), een eiwit dat een belangrijke rol speelt in de aangeboren afweer-
reactie. Polymorfi smen in het MBL2 gen beïnvloeden de aanmaak van het eiwit MBL. 
Sommige genotypen (bepaalde genetische variaties) leiden tot hogere concentraties 
van MBL in het bloed (hoge MBL spiegels) en andere genotypen tot lagere MBL spiegels. 
Patiënten met kanker van de bloedcellen (hematologische maligniteit) met genotypen 
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Figuur 1. Het metabolisme van irinotecan
Nadat irinotecan via het infuus is toegediend, wordt het verdeeld over het lichaam. Het wordt omgezet 
in de werkzame stof SN-38 door eiwitten genaamd carboxylesterases (CES), die voornamelijk aanwezig 
zijn in de lever, longen en darmen. Naast de omzetting van irinotecan in SN-38 kan irinotecan ook worden 
omgezet door CYP3A eiwitten in de niet-actieve stoff en APC en NPC. NPC kan vervolgens ook weer door 
CES worden omgezet in SN-38. SN-38 zelf kan worden geïnactiveerd door UGT1A eiwitten, waarvan 
UGT1A1 de belangrijkste is. Hierdoor wordt de inactieve stof SN-38G gevormd. Nadat SN-38G via de 
lever en galwegen is uitgescheiden in de darmen, kan het weer terug omgezet worden in SN-38 door 
bacteriën die het enzym β-glucuronidase (β-GLUC) maken. Er wordt verondersteld dat dit de oorzaak 
van de bijwerking diarree is, aangezien SN-38 schadelijk is voor de darmcellen. Naast alle genoemde 
metaboliserende enzymen, zijn er ook nog verschillende transport-eiwitten betrokken bij de uitscheiding 
van irinotecan. Deze transport-eiwitten spelen een rol in het opnemen (SLCO transport-eiwitten) en 
uitscheiden van irinotecan (ABC transport-eiwitten) en haar afbraakproducten in bepaalde organen van 
het lichaam, zoals de darmen en de nieren.
Copyright PharmGKB. Herdrukt met toestemming van PharmGKB en Stanford University.
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die zorgen voor lage MBL spiegels hebben mogelijk een verhoogd risico op infecties 
na chemotherapie. De in de literatuur beschreven resultaten zijn echter tegenstrijdig 
met elkaar en het is onbekend wat de invloed is van MBL op infecties bij patiënten 
die behandeld zijn met chemotherapie voor andere vormen van kanker. Hoofdstuk 
3 beschrijft het eff ect van genetische variaties in het MBL2 gen op het ontstaan van 
neutropene koorts (koorts in combinatie met een zeer lage hoeveelheid witte bloedcel-
len) na irinotecan behandeling bij 133 kankerpatiënten. Patiënten met genotypen die 
zorgen voor hoge MBL spiegels hadden signifi cant vaker neutropene koorts. Dit zou 
verklaard kunnen worden door een verhoogde activiteit van het immuunsysteem bij 
patiënten met genotypen die hoge MBL spiegels tot gevolg hebben, in vergelijking tot 
patiënten met genotypen die lage MBL spiegels geven.
Terwijl een groot deel van de toegediende dosis van irinotecan via de nieren wordt 
uitgescheiden in de urine, zijn er weinig gegevens bekend over de relatie tussen 
nierfunctie en de farmacokinetiek van irinotecan. In Hoofdstuk 4 is het eff ect van de 
werkzaamheid van de nieren (nierfunctie) op de farmacokinetiek en bijwerkingen van 
irinotecan onderzocht bij 187 kankerpatiënten. De kreatinine klaring (een maat voor de 
nierfunctie) werd berekend aan de hand van de zogenoemde Cockcroft-Gault formule 
en patiënten werden in categorieën ingedeeld aan de hand van hun nierfunctie. Er werd 
in dit onderzoek geen invloed gezien van de nierfunctie op de farmacokinetiek van iri-
notecan. Echter, patiënten met een verminderde nierfunctie hadden signifi cant vaker en 
meer ernstige neutropenie. Dit was voornamelijk het geval bij niet-rokende patiënten. 
Het is daarom te adviseren rekening te houden met de nierfunctie bij het bepalen van 
de toe te dienen irinotecan dosis.
Naast levensstijl en het voorkomen van andere ziekten (co-morbiditeit), kan het 
gelijktijdig gebruik van andere medicijnen die een invloed hebben op metaboliserende 
enzymen en transport-eiwitten een belangrijke rol spelen bij het eff ect van chemothe-
rapie. Het is bekend dat medicijn-interacties een belangrijke oorzaak zijn van het falen 
van behandelingen door het veranderen van de blootstelling en daarmee potentieel het 
verminderen van de werkzaamheid en het vergroten van de bijwerkingen. In de hoofd-
stukken 5 en 6 van dit proefschrift is de invloed van co-medicatie op de farmacokinetiek 
en bijwerkingen van irinotecan onderzocht.
Hoofdstuk 5 beschrijft een medicatie-interactie onderzoek tussen irinotecan en de 
vaak voorgeschreven maagzuurremmer omeprazol. Laboratoriumonderzoek liet zien 
dat omeprazol zorgt voor een verhoogde aanmaak van het enzym UGT1A1 en dat ome-
prazol zorgt voor een verminderde vorming van de niet-werkzame afbraakproducten 
van irinotecan, APC en NPC, door het enzym CYP3A. In het klinische onderzoek werden 
14 patiënten behandeld met 2 chemokuren irinotecan, één kuur met en één kuur zonder 
gelijktijdig gebruik van omeprazol. Er werd geen eff ect van omeprazol op de farmacoki-
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netiek en bijwerkingen van irinotecan gezien. Een standaard dosering omeprazol kan 
daarom veilig gecombineerd worden met een drie-wekelijkse irinotecan behandeling.
In Hoofdstuk 6 hebben we het eff ect van strumazol (een schildklierremmer) op de 
farmacokinetiek en bijwerkingen van irinotecan onderzocht bij een patiënt die behan-
deld werd met 4 kuren irinotecan, twee met en twee zonder strumazol. Er werd geen 
eff ect gezien van strumazol op de farmacokinetiek van irinotecan. De blootstelling aan 
de werkzame stof SN-38 was echter hoger in de kuren die gecombineerd waren met 
strumazol. Opvallend was dat de blootstelling aan SN-38G (het niet-werkzame afbraak-
product van SN-38) bijna dubbel zo hoog was in de kuren met strumazol. Dit leek te wor-
den veroorzaakt door een verhoogde aanmaak van het enzym UGT1A1 onder invloed 
van strumazol (UGT1A1 zorgt voor omzetting van SN-38 in SN-38G). Dit werd bevestigd 
in het aanvullende laboratoriumonderzoek. Aangezien hogere SN-38G spiegels in de 
darm lokaal ge(re)activeerd kunnen worden in SN-38, wat schadelijk is voor de darmen, 
is het mogelijk dat de combinatie van strumazol en irinotecan leidt tot een verhoogde 
kans op diarree.
Momenteel zijn er vele factoren bekend die bijdragen aan de grote variabiliteit in de 
farmacokinetiek van irinotecan tussen patiënten onderling (inter-patiënt variabiliteit). 
Het doseren van irinotecan gebeurt echter wereldwijd nog steeds op basis van de 
lichaamsoppervlakte (BSA) van een patiënt. Er werd gedacht dat een grotere of dikkere 
patiënt meer van het medicijn nodig heeft dan een kleinere of dunnere patiënt om het-
zelfde eff ect te bereiken. Dit lijkt logisch, maar voor irinotecan en vele andere chemo-
therapeutica is inmiddels aangetoond dat doseren op basis van lichaamsoppervlakte 
de inter-patiënt variabiliteit in de farmacokinetiek niet verkleint en de bijwerkingen niet 
vermindert en dus geen goede manier is om op ‘maat te doseren’. Daarnaast worden 
de meeste andere medicijnen, bijvoorbeeld paracetamol, ook in een vaste dosering 
gegeven. Voor irinotecan wordt daarom tegenwoordig geadviseerd om een vaste do-
sering van 600 mg te geven aan iedere patiënt in plaats van de geregistreerde dosis 
van 350 mg per m2 lichaamsoppervlakte. Dit is makkelijker en veiliger omdat er geen 
berekeningsfouten gemaakt kunnen worden. Het is echter nog steeds géén op maat 
berekende dosis en het zorgt niet voor minder bijwerkingen.
Om de behandeling van irinotecan te optimaliseren en werkelijk te individualiseren 
(voor iedere patiënt een op maat berekende dosis op basis van de karakteristieken 
van die patiënt), dient er een nieuwe manier van doseren ontwikkeld te worden die 
rekening houdt met de factoren die de farmacokinetiek en bijwerkingen van irinotecan 
beïnvloeden.
In Hoofdstuk 7 is een nieuwe doseringsformule ontwikkeld. Alle tot dusver bekende 
factoren die de farmacokinetiek van irinotecan zouden kunnen beïnvloeden werden 
meegenomen in de ontwikkeling van deze nieuwe formule, zoals leeftijd, lengte, ge-
wicht, lichaamsoppervlakte, aantal bloedcellen, lever- en nierfunctie en genetische va-
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riaties in het UGT1A1 gen. Genetische variaties in het UGT1A1 gen, waarvan UGT1A1*28 
de bekendste is, kunnen een invloed hebben op de farmacokinetiek en bijwerkingen 
van irinotecan, doordat er meer of minder van het eiwit UGT1A1 aangemaakt wordt, dat 
zorgt voor de afbraak van de werkzame stof SN-38 in de niet-werkzame stof SN-38G. Het 
resulterende doseringsmodel was gebaseerd op drie patiëntkarakteristieken: lengte, de 
waarde van y-glutamyltransferase (een bepaald levereiwit dat iets zegt over de afvloed 
van gal in de galwegen) en de activiteit van het enzym CYP3A. De activiteit van het eiwit 
CYP3A werd berekend door middel van het bepalen van de omzetting en uitscheiding 
(klaring) van het medicijn midazolam, dat ook door CYP3A wordt afgebroken (CYP3A 
probe). Deze techniek noemen we fenotyperen (Figuur 2). 
De drie patiëntkenmerken die uit het doseringmodel kwamen verklaarden tezamen 
bijna 80% van de variabiliteit in de uitscheiding van irinotecan. Dit is zeer hoog in ver-
gelijking met de variabiliteit die verklaard wordt door lichaamsoppervlakte, die slechts 
ongeveer 20% is. Vervolgens werd de nieuwe doseringsformule vergeleken met doseren 
op basis van lichaamsoppervlakte in een gerandomiseerd onderzoek met 40 kankerpa-
tiënten. Hoewel de spreiding van de doseringen die gegeven werden aan de patiënten 
in de formule-groep (380-1060 mg) veel breder was dan die in de lichaamsoppervlakte-
Probe drug
(midazolam)
PK
Probe-drug
Medicijn PK
Patiënt-karakteristieken Voorspelling
Overlap in 
afbraakroute
(irinotecan) Medicijn
Figuur 2. Fenotyperen
Door middel van het meten van de farmacokinetiek (PK) van een medicijn dat op dezelfde manier 
wordt afgebroken en uitgescheiden als het medicijn waarin men geïnteresseerd is, kan men een 
voorspelling doen van de farmacokinetiek van het medicijn van interesse. Het medicijn dat gebruikt 
wordt om de farmacokinetiek van een ander medicijn te voorspellen, noemt men een ‘probe drug’. Deze 
techniek noemt men fenotyperen. Hierbij wordt rekening gehouden met zowel genetische variaties 
(genotypering) als andere karakteristieken van de patiënt, die het metabolisme van een medicijn kunnen 
beïnvloeden. Het slaapmiddel midazolam wordt net als irinotecan afgebroken door het enzym CYP3A. 
Door voorafgaand aan de irinotecan kuur de farmacokinetiek van midazolam in de patiënt te bepalen, 
kan een voorspelling gedaan worden over de activiteit van het CYP3A eiwit bij die patiënt, waarmee een 
voorspelling van de farmacokinetiek van irinotecan kan gedaan worden.
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groep (480-800 mg) resulteerde het doseren met de nieuwe doseringsformule in een 
lagere inter-patiënt variabiliteit in de blootstelling aan irinotecan en de werkzame stof 
SN-38 en in een signifi cant minder voorkomen van ernstige neutropenie.
CONCLUSIE
Dit proefschrift introduceert nieuwe factoren die de farmacokinetiek en bijwerkingen 
van irinotecan beïnvloeden. Daarnaast is er een nieuwe doseringsstrategie voor het 
individualiseren van irinotecan behandeling ontwikkeld. Fenotyperen, oftewel de 
uitscheiding van een geneesmiddel voorspellen op basis van de uitscheiding van een 
ander geneesmiddel dat op de zelfde wijze wordt afgebroken en uitgescheiden, kan 
mogelijk behulpzaam zijn bij het individualiseren van het doseren van irinotecan, 
aangezien het rekening houdt met verschillende patiëntkarakteristieken die de werking 
van metaboliserende enzymen beïnvloeden. Het is echter behoorlijk arbeidsintensief en 
vereist een goede samenwerking tussen de kliniek en de laboratoria waar de metingen 
worden gedaan. Om deze reden zouden er simpelere strategieën ontwikkeld moeten 
worden waarbij slechts beperkte, of liever nog géén, bloedbuizen van de patiënt nodig 
zijn. Een andere optie zou het aanpassen van de dosering op basis van de berekende 
blootstelling kunnen zijn (het zogenoemde ‘therapeutic drug monitoring’).
In het huidige tijdperk van ‘op maat behandelen‘ is nog een weg te gaan voor de 
behandeling met irinotecan. Hoewel nieuwe factoren toegevoegd kunnen worden aan 
de gereedschapskist van geïndividualiseerde irinotecan behandeling, blijven er nog 
vele niet-ontdekte factoren. Een belangrijke vraag die nog beantwoord moet worden is 
hoe de wisselwerking van alle momenteel bekende factoren van invloed is op de werk-
zaamheid van irinotecan. In het algemeen wordt aangenomen dat de werkzaamheid 
van chemotherapie gerelateerd is aan de blootstelling aan het medicijn, maar hier zijn 
geen harde bewijzen voor.
Nieuwe onderzoeken met kleine aantallen patiënten zullen waarschijnlijk geen 
waardevolle informatie toevoegen. Om uiteindelijk alle overgebleven vragen te kunnen 
beantwoorden, zullen onderzoeksgroepen meer moeten gaan samenwerken en hun 
patiëntengegevens uit farmacokinetische, farmacodynamische en farmacogenetische 
onderzoeken en fase III onderzoeken (waarin de eff ectiviteit van een geneesmiddel 
wordt onderzocht) moeten uitwisselen en combineren om grote groepen patiënten te 
creëren waarin relevante vraagstellingen kunnen worden onderzocht. Bovendien zou 
farmacologisch onderzoek ingebed moeten worden in fase III onderzoek en fase IV 
onderzoek (onderzoek dat wordt gedaan nadat het medicijn op de markt is gebracht), 
bij voorkeur op een manier waarbij een minimaal aantal bloedbuizen nodig is, om de 
relatie tussen blootstelling aan een medicijn en de werkzaamheid ervan te onderzoeken 
en te bevestigen.
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